

INFORMAZIONI PERSONALI

Oliva Esther Natalie

 Via C. Quattrone 8, 89134 Reggio Calabria (Italia)

 + 39 0965 393903

 enoliva@gmail.com

Cittadinanza Italiana

Data di nascita 03/04/1966

Sesso Femminile

Codice Fiscale LVOSHR66D43Z401F

Numero d'iscrizione
all'Albo Professionale n. 6398 del 12/02/1991

Albo Provinciale dei Medici Chirurghi di REGGIO DI CALABRIA

POSIZIONE RICOPERTA Dirigente Medico

ESPERIENZA PROFESSIONALE

1999–alla data attuale

Dirigente Medico I livello

Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria (Italia)

Divisione di Ematologia: contribuendo principalmente alla gestione della Corsia, del Day Hospital e dell'attività ambulatoriale nell'ambito delle Sindromi Mielodisplastiche e delle Anemie

1992–1997

Istituto di Ricerca " Mario Negri". Via la Masa 19 - Milano

Borsa di studio dell'Istituto di Ricerche Farmacologiche "Mario Negri" per lo studio REIN (Ramipril Efficacy in Nephropathy) Divisione di Nefrologia - Centro di Fisiologia Clinica del CNR di Reggio Calabria:

1990–1992

Istituto di Immunologia, Messina (Italia)

Borsa di studio finalizzata alla ricerca di "Fattori di rischio ed incidenza di malattie gastrointestinali croniche in rapporto all'assetto alloantigenico MHC e all'inibizione della espressione di markers isotipici linfocitari"; Istituto di Immunologia, Messina

ISTRUZIONE E FORMAZIONE

2018-2024 Abilitazione scientifica nazionale a professore di Malattie del Sangue, Oncologia e Reumatologia di Fascia II dal 31-10-2018 al 31-10-2024

1997–1998 **Specializzazione in Nefrologia**

Università degli Studi di Catanzaro

1994 **Specializzazione in Ematologia**

Università degli Studi di Messina- Pzza S. Pugliatti, 1 - Messina

1990 Laurea in Medicina e Chirurgia

Università degli Studi di Messina- Pzza S. Pugliatti, 1 - Messina

COMPETENZE PERSONALI

Lingua madre Inglese

Altre lingue

	COMPRENSIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Italiano	C2	C2	C2	C2	C2
Francese	B2	B2	B1	B1	B1
Spagnolo	C1	C1	B2	B2	B2
Tedesco	B1	B1	B1	B1	B1

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze digitali

AUTOVALUTAZIONE				
Elaborazione delle informazioni	Comunicazione	Creazione di Contenuti	Sicurezza	Risoluzione di problemi
Utente autonomo	Utente autonomo	Utente autonomo	Utente autonomo	Utente base

Competenze digitali - Scheda per l'autovalutazione

Internet, Word, Powerpoint, Excel, Paintbrush, SPSS (software di statistica avanzata)

Altre competenze

Capacità di stesura e coordinamento di sperimentazioni cliniche multicentriche e esperienza nella conduzione di studi clinici secondo le Buone Norme di Pratica Clinica. (GCP/ICH).

Capacità di stesura e revisione di lavori scientifici

capacità di analisi statistiche descrittive e inferenziali

ULTERIORI INFORMAZIONI

Membro dei seguenti gruppi:

Rappresentante regionale (Calabria-Basilicata) della Società Italiana di Ematologia Sperimentale SIES

Società Italiana di Ematologia SIE

American Society of Hematology ASH

International society of quality of life

European Hematology Association EHA

Comitato Scientifico dell'Associazione Italiana dei Pazienti con Sindrome Mielodisplastica Onlus (AIPaSiM)

Comitato Scientifico dell'Associazione QOL-ONE per la ricerca sulla qualità della vita nei pazienti affetti da malattie ematologiche

Comitato Scientifico MDS Diagnosis per il sito mdsdiagnosis.com

**Membro del
Consiglio Direttivo di:**

Associazione QOL-ONE- Membro fondatore dal 2007, Presidente dal 2014 al 2019. Vice Presidente dal 2019

European Hematology Association Scientific working group for Quality of Life and Symptoms
Project coordinator dal 2012, Presidente dal 2014 al 2018, Vice Presidente dal 2019.

Brevetti:

Autrice di QOL-E, strumento di misurazione della qualità di vita nelle sindromi mielodisplastiche.

Autrice di HM-PRO, strumento di misurazione della qualità di vita e sintomi nei pazienti affetti da emopatie maligne.

Altre informazioni

Membro del Consiglio Editoriale della rivista HemaSphere dal 2019

Membro del "Question Writers Group" dell' "European Hematology Passport Examination" della European Hematology Association dal 2017

Membro della Faculty EHA Hematology Tutorials

Membro dell'International MDS Guideline Working group 3 dal 2022

Membro dell'Expert Panel of the EHA-ERICI Guidelines, 2023

Editore di American Journal of Blood Research

Editore della sezione Hematological Malignancies della rivista Frontiers in Oncology dal 2021

Editore della raccolta speciale "Health-Related Quality of Life Among Hodgkin Lymphoma Survivors" della rivista Frontiers in Oncology, 2022

Editore associato per la rivista Frontiers in Oncology – Hematologic Malignancies.

Guest Editor di Journal of Clinical Medicine sezione speciale "Myelodysplastic Syndrome: Recent Advances and Future Directions" 2022

Guest Editor di Cancer, sezione speciale "Chemotherapy for Hematologic Malignancies", 2023

Direttore Scientifico del periodico di aggiornamento medico: Ematologia e dintorni

Esaminatore dell'"European Hematology exam" dell'European Hematology Association dal 2017

Revisore degli abstract al congresso EHA dal 2015

Revisore degli abstract al congresso abstract SIE dal 2014

Revisore coordinatore e moderatrice di sessione EHA 2020 e 2021

Relatrice per il Webinar "Blood and Beyond: Rethinking Blood Use", marzo 2020

Revisore degli MDPI journals 2021

Autore e Revisore di numerose riviste internazionali

Expert panel per creazione documento di consenso per la gestione del paziente con ITP e vaccino anti-COVID-19, dicembre 2021

2007

- 10-12 settembre 2007
LE SINDROMI MIELODISPLASTICHE: DALLA TEORIA ALLA PRATICA; Bologna
Docente: "Il problema della "Quality of Life". Metodi di valutazione in funzione della scelta terapeutica"; 11 settembre, Ore 16:00-17:00

2008

- 30 marzo -2 aprile 2008
34th Annual Meeting of the European Group for Blood and Marrow Transplantation; Firenze
Relatrice: "Use of the KGF (Palifermin) but not of G-CSF is associated rto a reduced rate of infections after high dose chemotherapy and autologous PBSC Transplantation."
- 12 aprile 2008
MDS Iron Forum. Practical use of deferasirox in transfused iron-overloaded MDS patients; Amsterdam.
Relatrice: Case presentation
- 19 aprile 2008
Corso di aggiornamento ECM Ruolo del Ferro nelle mielodisplasie. La terapia trasfusionale delle mielodisplasie: è possibile definire uno standard ?; Caltanissetta
- 10 maggio, 2008
Il Management dei pazienti con Mielodisplasia ed Emosiderosi: nuove prospettive terapeutiche nella ferrochelazione; Palmi (RC)
Relatrice: "Mielodisplasia e accumulo di ferro: importanza della ferro chelazione"
- 13 maggio 2008
Percorsi diagnostici e opzioni terapeutiche nelle sindromi mielodisplastiche. La prognosi; Ancona
- 3-5 luglio 2008
Evidence-Based Medicine in Ematologia: Corso Avanzato di Biostatistica di Base con SPSS; Hotel Alta Fiumara, Reggio Calabria
Organizzatrice e Tutor
- 12 e 13 settembre 2008
Attualità e Prospettive in Oncoematologia; Palermo
Relatrice: "Sindromi Mielodisplastiche. Trattamento dell'anemia"
- 25 ottobre 2008
Corso Regionale SIE. Aggiornamento sulle Leucemie Acute non linfoidi dell'anziano e malattie Mieloproliferative croniche; Reggio Calabria
Relatrice: "Qualità di vita nelle leucemie acute non linfoidi dell'anziano"
- 28 novembre 2008
Progetto per l'Oncologia e l'Ematologia Italiana. Linee guida: ribellarsi, adeguarsi o contribuire?"; Hotel Excelsior, Reggio Calabria
Relatrice: Sessione Qualità della Vita e Consenso Informato- "Evoluzione del concetto di

Qualità della Vita nel paziente oncoematologico”; ore 11:15-12:00

2009

- 18-19 settembre 2009
Aggiornamenti in Ematologia dal Laboratorio alla Clinica, Palazzo Arnone, Cosenza
Relatrice: Sessione Le Sindromi Mielodisplastiche - Aspetti Biologici “Nuovi approcci terapeutici: la lenalidomide e i farmaci ipometilanti”; 19 settembre
- 25 settembre 2009
L’anemia nell’anziano. Percorsi Diagnostici e Terapeutici; Padova
Relatrice: “Epidemiologia e patogenesi”
- 16 novembre 2009
Le Sindromi Mieloproliferative nell’anziano; Roma
Relatrice: “Sentirsi giovani con la TE”; ore 12:10-12:30
- 23-25 novembre 2009
MDS: biologia, fisiopatologia, clinica e nuove prospettive terapeutiche; Bologna
Relatrice: Sessione Diagnosi e Prognosi “La valutazione della qualità di vita”; 24 novembre, ore 17:00-18:00
- 28 novembre 2009
2° Corso di Formazione in Oncologia-Qualità di vita e complicanze del paziente oncologico; Hotel Guglielmo, Catanzaro
Relatrice: “Il futuro della terapia con fattori eritropoietici”; ore 11:00-11:20

2010

- 29-30 aprile 2010
MDS Expert Meeting; Hotel Hilton, Roma
Moderatrice: “Il paziente a rischio IPPS basso/ INT 1”
- 28-29 maggio 2010
La terapia delle Sindromi Mielodisplastiche: Un vestito fatto su misura; Hotel de la Ville, Avellino
Relatrice: “Anemia e QoL: l’importanza nella gestione del paziente con diagnosi di sindrome mielodisplastica”; 28 maggio, ore 16:15
- 7 maggio 2010
L’anemia nell’anziano. Percorsi Diagnostici e Terapeutici; Perugia
Relatrice: “2° Caso clinico Percorsi terapeutici delle sindromi mielodisplastiche Televoter”
- 13-15 settembre 2010
Stage Appunti sulla gestione del paziente con sindrome mielodisplastica; Aemilia Hotel, Bologna
Docente: “E’ giustificato posporre il più a lungo possibile l’inizio della terapia trasfusionale?”; 13 settembre
- 24 settembre 2010
L’anemia nell’anziano. Percorsi Diagnostici e Terapeutici; Pescara
Relatrice: “Percorsi terapeutici sindromi mielodisplastiche Televoter”; ore 14:00-14:20
- 28-29 ottobre 2010

Masterclass in Ematologia 2010. Cavalcando alcuni argomenti in attesa di risposta; Grand Hotel Dino, Baveno (VB).

Relatrice: Sessione MDS: ipermetilazione e ipometilanti- "Impiego degli ipometilanti e risultati"; 29 ottobre 2010

- 26 novembre 2010
Brainstorming Meeting. Patient -reported outcomes in patients with multiple myeloma and myelodysplastic syndrome: application for clinical trials; Freising, Germania
Relatrice: Sessione Quality of Life and Syntomp Assessment in Patients with Myelodysplastic Syndrome. "PRO in patients with myelodysplastic syndrome"

2011

- 15-16 aprile 2011
Xuzhou International Conference of Hematology; Xuzhou, Cina
Relatrice: "Biological changes during lenalidomide treatment in low and intermediate -1 risk Myelodysplastic Syndromes with Del (5q)"
- 24 maggio 2011
Myelodysplastic syndromes documentation: Best practice in the treatment with hypomethylating agents; Sheraton Catania Hotel, Aci Castello (Catania)
Relatrice: "Interpretazione di casi complessi con risposte interattive"
- 12-14 settembre 2011
Sindromi mieloproliferative croniche JAK2 mutate; Aemilia Hotel, Bologna
Relatrice: "La Qualità di vita nei pazienti con sindromi mieloproliferative croniche Ph"; 13 settembre, ore 16:30-17:30
- 14-15 ottobre 2011
La Sindrome Nefrosica. Nuove frontiere; Mondello (Palermo)
Relatrice: I Sessione Epidemiologia e Podocitopatie- "Low responders alla terapia con ESA"; 14 ottobre
- 28-29 ottobre 2011
Corso di aggiornamento Leucemie acute non linfoidi dell'anziano e Mielodisplasie; Reggio Calabria
Docente: "MDS alto rischio"
- 21-22 novembre 2011
Anemia Mangement Update meeting; Vienna, Austria
Relatrice: "Quality of Life in Myelodysplastic Syndromes"
- 25 novembre 2011
AIL Pazienti Mielodisplasie; Reggio Calabria
Relatrice: "La Qualità della Vita nei pazienti MDS"; ore 16:10-16:40
- 29 novembre 2011
Telesto Investigator Meeting; Milano
Relatrice: "La somministrazione del consenso: l'esperienza maturata"

2012

- 5- 8 maggio 2012
17° Congresso Nazionale FADOI; Rimini
Relatrice: "Le terapie delle sindromi mielodisplastiche"; 8 maggio; ore 9:55 10:20

- 10 maggio 2012
Achieve and maintain high response in hematology; Hilton Sorrento Palace, Sorrento (SA)
Relatrice: Workshop SMD-1 "Efficacia del trattamento con Vidaza"
- 8--9 giugno 2012
Le malattie del metabolismo del ferro; Avellino
Relatrice: "Azacitidina, lenalidomide, deferasirox: il miglioramento della QOL nei pazienti con diagnosi di mielodisplasia"; 9 giugno, ore 10:45
- 4 luglio 2012
Rapid fire in Hematology-Esperienze cliniche a confronto sulle Sindromi Mielodisplastiche e sulla Leucemia Mieloide Acuta; Hotel NH Parco degli Aragonesi, Catania
Relatrice: "Presentazione casi clinici e discussione interattiva (con televoter) sulle strategie terapeutiche nelle SMD"; ore 10:45-11:00
- 26-27 settembre 2012
Attualità e Prospettive in Oncoematologia X Edizione; Palermo
Relatrice: Sessione Sindromi Mielodisplastiche e Leucemie Acute - "Terapia di supporto ed ESA"; ore 12:00-12:30
- 26 ottobre 2012
The value of PROs in clinical practice in patients with hematological malignancies; Marriot Hotel, Budapest
Relatrice: Sessione Why do physicians need to assess patient-reported outcomes in patients with hematological malignancies- "Value of patient-reported outcomes in hematological clinical practice", ore 09:30-09:45; Sessione The EHA SWG Project The value of PROs in clinical practice in patients with hematological malignancies - "The rationale of a study "The value of PROs in clinical practice in patients with hematological malignancies", ore 14:15-14:30
- 14 novembre 2012
Percorsi diagnostico terapeutici nelle SMD: Da una corretta diagnosi verso nuove opzioni terapeutiche; Perugia
Relatrice: Sessione III - "Appropriatezza Terapeutica nelle Sindromi Mielodisplastiche"; ore 16:45-17:30
- 29 novembre 2012
Citopenia nell'anziano, un problema emergente: dalla diagnosi alla terapia; Roma
Moderatrice: Sessione Peculiarità clinico diagnostiche delle anemie

2013

- 22-23 marzo 2013
Congresso Ridefinire la ferro chelazione; Milano
Relatrice: "Trasfusione-dipendenza e Qualità della Vita"
- 21-23 maggio 2013
EPS 2° Annual International Symposium of Hematology; Xi'an, Cina
Relatrice: "Treatment Strategies in Myelodysplastic Syndromes"
- 27 giugno 2013
Congresso Rapid Fire in Hematology; Catania
Relatrice: "Stato dell'arte nelle SMD: prospettive di cura ed efficacia a lungo termine"
- 25-28 settembre 2013
25° Congress of Polish Hematologists and Transfusiologists; Poznan Polonia

Relatrice: “Patients with LR MDS with del5q management”; 26 settembre

- 11-12 ottobre 2013
Convegno HematoForum- Qualità della cura ed etica della salute
Relatrice
- 13 novembre 2013
Congresso Le Sindromi Mielodisplastiche: dalla diagnosi alla gestione multidisciplinare del paziente; Reggio Calabria
Relatrice: “Strategie terapeutiche nelle SMD”
- 26 novembre 2013
Corso L'appropriatezza dell'uso di emocomponenti in Medicina Trasfusionale; Reggio Calabria
Relatrice: “Il sovraccarico marziale nei pazienti trasfusione-dipendenti”
- 29 novembre 2013
Congresso Tra Storia, Cultura e Medicina: La Galleria Nazionale di Cosenza Ospita l'Ematologia Calabro-Lucana. Sfide e Questioni non Risolte in: MDS-MM-CLL-AML-NHL; Cosenza
Relatrice: “Introduzione alle Sindromi Mielodisplastiche”
- 29- 30 novembre 2013
Congresso FADOI Regionale; Scalea (CS)
Relatrice: “linica, Diagnosi e Terapia Innovativa delle Mielodisplasie”

2014

- 9 maggio 2014
MDS Leading Experts Forum; Seul (Corea)
Relatrice: “Transfusion for anemia-A double-edged sword”; “The dark side of iron: Clinical consequences of iron overload”
- 21-24 maggio 2014
3° International Conference Leukemia 2014; Santa Margherita Ligure, Portofino
Relatrice: Sessione Myelodysplastic Syndromes- “Low -risk patients with deletions in chromosome 5”; 23 maggio; ore 17:00-17:20
- 24-25 giugno 2014
“MDS Day: il percorso del paziente con sindromi mielodisplastiche”, Napoli
Relatrice: Sessione La Clinica - “Trattamento delle MDS a basso rischio”; 25 giugno; ore 08:30-08:50
- 30 giugno 2014
AB “Sindromi Mielodisplastiche con elezione del 5q-Diagnosis and Sharing of Clinical Experience”; Milano
Relatrice: “Lenalidomide nel trattamento delle sindromi mielodisplastiche con del5q: efficacy and effectiveness”; ore 12:15-13:00
- 3 settembre 2014
Celgene Del(5Q) Sounding Board workshop; Zurigo, Svizzera
Relatrice: “Clinical overview of lenalidomide in MDS del(5q)”; ore 11:10-11:40
- 25 settembre 2014

2° National Iron Diagnostic Roundtable; Berna, Svizzera

Relatrice: "Key note lecture about diagnosis of IOL and iron chelation as part of the MDS patients management in Italy"

- 27 settembre 2014
MDS Symposium; Mosca (Russia)
Relatrice: "Tackling iron overload- A guide to optimal management"
- 29-30 settembre 2014
Convegno "Effective cancer therapy through immunomodulation"; Milano
Relatrice: "Equilibrio tra efficacia e tollerabilità: farmaci orali e qualità di vita"; ore 17:40-18:10
- 8 ottobre 2014
Convegno "Clinical Management of MDS Introduction to CMML Clinical Management of Older AML Patients and those unfit for intensive therapy"; Baveno
Relatrice: "Clinical Management of MDS Introduction to CMML Clinical Management of Older AML Patients and those unfit for intensive therapy"
- 10-11 Ottobre 2014
"Workshop Multimediale - Iter Diagnostici e Terapeutici in Ematologia; Reggio Calabria
Docente: Produzione Casi Clinici Interattivi
- 26 Ottobre 2014
Congresso SIMI "Anemie refrattarie ed altre mielodisplasie: nuove modalità diagnostiche e terapeutiche- Nuove strategie terapeutiche"; Roma
Relatrice: Workshop Anemie refrattarie ed altre mielodisplasie: nuove modalità diagnostiche e terapeutiche - "Nuove strategie terapeutiche"
- 13-14-22 novembre 2014
7° Corso di Formazione in oncologia ed ematologia: L'anziano con patologia oncologica ed ematologica nella sanità del futuro: prospettive terapeutiche e sostenibilità; Hotel Guglielmo, Catanzaro
Relatrice: "Terapia ferrochelante nelle sindromi mielodisplastiche"; 14 novembre, ore 14:45-17:15
- 22 novembre 2014
Nuovi orizzonti nelle Neoplasie Mieloproliferative Croniche Ph; Palazzo dei Congressi. A.O.U. G. Martino, Messina
Relatrice: "La Terapia di supporto: ruolo della ferro chelazione nei pazienti trasfusione dipendenti"

2015

- 9-10 gennaio 2015
Current & Future perspectives of MM & other hematological malignancies; Varsavia, Polonia
Relatrice: "Practical recommendations of lenalidomide treatment of lower risk MDS patients"
- 12-14 febbraio 2015
"Novità dal Meeting della Società Americana di Ematologia"; Palazzo della Gran Guardia, Verona
Relatrice: Sessione Sindromi Mielodisplastiche - "Sindromi mielodisplastiche: basso rischio"; 13 febbraio, ore 14:30-14:20

- 13-14 marzo 2015
QOL-ONE Investigator Meetings; Taormina (ME)
Relatrice: Sessione QoLESS AZA "Interim results of the protocol QoLESS –AZA-AMLE" (A randomized Study to Evaluate the Efficacy of 5-Aza for Post –Remission Therapy of Acute Myeloid Leukemia in Elderly Patients); 13 marzo, ore 15:40-16:00;
Sessione EQOL-MDS "Therapeutic options in lower risk MDS"; 13 marzo, ore 17:30 - 17:45;
Sessione Myelodysplastic syndromes with isolated del5q "Translational research project on the prognostic role of TP53 mutations in myelodysplastic syndromes with del5q"; 14 marzo, ore 9:30-10:00; "Lenalidomide treatment in myelodysplastic syndromes: focus on adverse events"; 14 marzo, ore 10:40-11:00; " Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study"; 14 marzo, ore 11.00-11.30
- 10-11 Aprile 2015
Convegno "Deferasirox: Camminando insieme alla Ferrochelazione"; Cagliari
Relatrice: Sessione Oncoematologica- La gestione della ferrochelazione nel paziente MDS TD "Qualità della vita del paziente"; 10 aprile, ore 18:00-18:30
- 22-23 maggio 2015
4th International Conference Leukemia 2015; Santa Margherita Ligure (GE)
Relatrice: "Treatment of low-risk"; 22 maggio, ore 14:25-14:45
- 1-2 Luglio 2015
Congresso "MDS Day 2015"; Bari
Relatrice: "Equilibrio tra tollerabilità e qualità di vita"; 1luglio, ore 15:25-15:55
- 9 luglio 2015
"Celgene AML Sounding Board Workshop; Zurigo (Svizzera)
Relatrice: "Treating AML patients with azacitidina: experience of Co-Chair"
- 31 agosto- 3 settembre 2015
Riunione di Ciclo Exjade"; Verbania
Relatrice: "La gestione della terapia ferrochelante nel paziente con sindrome mielodisplastica"; 1settembre, ore 11:30-13:00
- 28 settembre 2015
Focus Sindrome Mielodisplastica e Leucemia Acuta: Nuove acquisizioni terapeutiche e Trapianto di cellule staminali; Pescara
Relatrice: "Qualità di vita e compliance terapeutica nel paziente con sindrome mielodisplastica"; ore 14:00-15:30
- 7 ottobre 2015
Congresso "Treating Acute Myeloid Leukemia"; Londra (UK)
Relatrice: Plenary: Treating AML (>20% blasts); ore 09:30-10:30
- 10-12 ottobre 2015
Congresso SIMI "Gammopatie monoclonali evolutive e mielodisplastiche: sistemi diagnostici e nuove modalità terapeutiche"; Congress Center Rome Cavalieri Roma
Relatrice: 11 ottobre 2015 ore 12.45 "Il confine tra anemie e sindromi mielodisplastiche: dalla diagnosi alla terapia"
- 30 ottobre 2015
Il ruolo oggi della Terapia Ferrochelante nelle Mielodisplasie; Hotel Vechio Mulino, Monopoli (BA)

Relatrice: "Gestione della risposte del rene alla terapia ferrochelante"; ore 12:00-12:20

- 13-14 novembre 2015
WORKSHOP Multimediale Iter Diagnostici e Terapeutici in Ematologia; Reggio Calabria
Relatrice: 3° Sessione MetaPAD- "Dibattito tra Ematologo e Trapiantologo nelle MDS"; 13 novembre, 09:30- 10:15
- 16 novembre 2015
Advisory Board Meeting on Treatment Options in AML >30%; Brussels (Belgio)
Relatrice: "Treatment options in elderly AML patients with > 30% blasts"; ore 08:15-08:45
- 12 dicembre 2015
IMAN Investigator Meeting; Fatima (Portogallo)
Relatrice: "Transfusional iron overload in patients with myelodysplastic syndromes (MDS)"; ore 10:15-11:15

2016

- 5-6 febbraio 2016
Congresso "QOL-ONE Investigator Meeting 2016-Unmet needs in Low-Risk Myelodysplastic Syndromes", Siracusa
Relatrice: Sessione Eltrombopag for the treatment of thrombocytopenia due to low -and intermediate risk myelodysplastic syndromes EQOL-MDS meeting - "Therapeutic options in lower risk MDS"; 5 febbraio, ore 15:00 - 15:15;
Sessione The Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo-controlled study QOL-ONE Rev2MDS "QOL-ONE Rev2MDS protocol: Endpoints, Materials and Methods"; 5 febbraio, ore 17:30-18:00
- 3-5 marzo 2016
Congresso "IV Eurasian Hematology forum", San Pietroburgo (Russia)
Relatrice: "Treatment strategies and quality of life in elderly AML patients"; 4 marzo, ore 11:55; "Quality of life issues important to patients with hematological malignancies"; 4 marzo ore 18:50
- 10-11 marzo 2016
Mds Workshop; Varsavia (Polonia)
Relatrice: "Quality of life of patients suffering from myelodysplastic syndromes"; 11 marzo
- 18-19 marzo 2016
Convegno "Revolution on Thrombocytopenia Management", Milano
Relatrice: "Sindromi Mielodisplastiche", 19 marzo, ore 14:30-15:15
- 31 marzo 2016
Convegno "Focus on AML"; Roma
Relatrice: "La Leucemia Mieloide Acuta"; "Le terapie nel paziente fit ad un approccio aggressivo"; "Le terapie nel paziente unfit ad un approccio aggressivo"
- 6-7 aprile 2016
VIII Giornate di Aggiornamento Medico: Attualità e opinion correnti in medicina interna; ÈHotel, Reggio Calabria
Relatrice: "Il management delle mielodispalsie"; 7 aprile, ore 08:35-09:00

- 9 aprile 2016
"5th Congress of Slovenian Hematological Society"; Slovenia
Relatrice: "Presentation on clinical experiences with treating iron overload patients with EXJADDE"
- 16 aprile 2016
"Eltrombopag SAA Launch Meeting"; Porto (Portogallo)
Relatrice: "Experiences with treating patients with SAA"; ore 19:00-19:40
- 20 maggio 2016
"Bridge Educational Meeting"; Polonia
Relatrice: "Treating older patients with AML"; "Key therapeutic challenges and the clinical benefits of using azacitidine"
- 21-22 giugno 2016
Convegno "MDS PATHway - Iter diagnostico terapeutico nelle Sindromi Mielodisplastiche e LAM 20"; Lifestyle Hotel, Via Giorgio Zoega, 59, 00164 Roma
Relatrice: Sessione 2^ "Strategie terapeutiche nelle MDS a basso rischio"; 22 giugno, ore 11.00
- 28 giugno 2016
Congresso "2nd European Scientific Seminar (NOESS) Towards Personalized Cancer Therapy: The Role of the Host, the Tumor, and the Tumor Microenvironment"; Maritim Hotel, Berlino, Germania
Relatrice: "Current and Future Treatment Landscape in MDS"; ore 08:20-08:40
- 16-17 settembre 2016
Congresso "QOL-ONE MDS and AML Meetings"; Palazzo del Consiglio Regionale, Reggio Calabria
Relatrice: "Quality of Life of patients with MDS"; 16 settembre, ore 15:30-16:00
- 1 ottobre-30 settembre 2016
Congresso "6th International ITP Assembly"; Novotel Amsterdam City, Amsterdam, The Netherlands
Relatrice: Special interest workshop rotation 1- "MDS and thrombocytopenia"; 1 ottobre, ore 12:05-12:50
- 4-5 Ottobre 2016
Advisory board: "Key Opinion Leader Meeting"; Milano
Relatrice: "Myelodysplastic Syndrome and Hepcidin"
- 14 Ottobre 2016
Convegno "Bridge Meeting"; Polonia
Relatrice: "Treating older patients with AML"; "Key therapeutic challenges and the clinical benefit of using azacitidine"; ore 11:05-11:45
- 26-27 ottobre 2016
Epalco Meeting; Novartis Oncology Region Europe Headquarters, Origgio (VA), Italia
Relatrice: "Addressing disparities in how patients, payers, clinicians and industry perceive the relevance of patient reported outcomes (PROs)"; 27 ottobre, ore 09:45
- 26 Ottobre 2016
Seminario "Sindrome Mielodisplastica e ruolo della chelazione"; Roma
Relatrice: "Terapia Ferrochelante nelle MDS"
- 11 novembre 2016

Convegno “Bridge Meeting in AML – Building the Bridge”; Atene (Grecia)

Relatrice: “Interactive discussion 1: AML Diagnosis & Classification, Current Treatment options for older patients with AML”; “Interactive discussion 2: Azacitidine in the treatment of elderly patients and management of AEs (AZA-AML-001)”; “Interactive discussion 3: Real World Data: Austrian Registry - Azacitidine in AML in Real Life”; ore 15:30-17:15

- 23 - 24 novembre 2016
Convegno “Neoplasie di Origine Mieloide: Uno scenario in Evoluzione”; Convitto Della Calza, Pi Piazza della Calza, 6 - 50125, Firenze
Relatrice: Sessione I^ Sindromi Mielodisplastiche “Nuovi farmaci e QoL nel paziente a basso rischio”; 23 novembre, ore 15:40
- 25 novembre 2016
Advisory Board “Il ruolo dell'azacitidina nella terapia della Leucemia Mieloide Acuta”; Sede Celgene Italia Milano
Relatrice: “Azacitidina nella Leucemia Mieloide Acuta: le evidenze nel mantenimento della risposta”; ore 14:00-15:00
- 29 novembre 2016
Convegno “La Malattia Minima Residua nelle Patologie Ematologiche”; Hilton Hotel Sala Brussels, Via Luigi Galvani, 12 Milano
Relatrice: “Valutazione e monitoraggio delle Sindromi Mielodisplastiche ed Emoglobinuria Parossistica Notturna”; ore 15:15
- 14 dicembre 2016
Convegno “Bridge Educational Meeting”; Madrid (Spagna)
Relatrice: “Azacitidine in older patients with AML: clinical trial and ‘real-world’ data”; ore 16:10–16:55

2017

- 21-22 aprile 2017
Congresso “AML Regional Experts Meeting”; Dubai
Relatrice: “The Value of Care in AML”; 21 aprile; Treatment Strategies & Outcomes in Older AML Patients”; “Improving the Outlook for AML Patients: New Treatment Options”; 22 aprile
- 27-29 Aprile 2017
Congresso “Iron Overload Meeting”; Porto (Portogallo)
Relatrice: “Trends and strategies for the clinical use of TPO-r agonists”; 27 aprile; “Iron overload on MDS patients-From diagnosis to treatment & monitoring”; 28 aprile
- 10 Giugno 2017
Convegno “L'attuale Approccio Clinico al Paziente con Sindrome Mielodisplastica”; Hotel Mediterraneo Via Ponte di Tappia, 25 Napoli
Relatrice: “Il trattamento del paziente con piastrinopenia”; ore 15.00
- 1-2 Settembre 2017
Congresso “QOL-ONE International Conference on Updates in Hematology”; Palazzo del Consiglio Regionale Reggio Calabria
Relatrice: Sessione ACUTE MYELOID LEUKEMIA “Treatment of unfit patients with AML”, 2 settembre, ore 11:00-11:30
- 23 Settembre 2017
Convegno “L'evoluzione della Terapia con TPO Mimetici dalla ITP alle MDS, T-HOTEL -

SS280 Lamezia - Catanzaro, 88040 - Loc. Garrubbe, Feroletto Antico CZ.
Relatrice: Sessione II "MDS e TPO MIMETICI", ore 16.45

- 25-26 Settembre 2017
Convegno "Terapie Personalizzate nelle Neoplasie Mieloidi" II edizione; Hotel Sheraton four points Via Gerolamo Cardano,1 Milano
Relatrice: Sessione II "Terapia personalizzata del paziente ad alto rischio"; 26 settembre, ore 11.30
- 29 settembre 2017
Congresso "Tailored treatment strategies in Myeloid malignancies"; Grupama Arena, Budapest, Ungheria
Relatrice: "Role of Azacitidine in MDS and AML"; ore 15:40
- 5-8 ottobre 2017
Congresso "National Conference of Hematology"- "With experience comes confidence"; Majestic, Sunny Beach resort, Burgas
Relatrice "Vidaza -the standard front-line treatment for intermediate-2 and high risk MDS patients"; 6 ottobre, ore 16:45
- 9 ottobre 2017
Advisory board "Sviluppo di uno strumento per valutare la qualità di vita correlata alla salute nei pazienti con malattia di Gaucher"; Genova
Relatrice: "Il valore della misurazione dei PRO (patients reported outcomes) nei trial e nella pratica clinica- QOL-ONE PRO-1G: sviluppo e validazione di uno strumento per la valutazione della qualità della vita nei pazienti con malattia di Gaucher"; ore 15:10
- 10-11 novembre 2017
Evento "Recenti progressi in ematologia"; Auditorium "Fra Agostino Daniele", San Giovanni Rotondo (FG)
Relatrice: Sessione "Una nuova era in ematologia?" "Nella Mielodisplasia"; 11 novembre, ore 11:00
- 13-14 novembre 2017
Evento ECM "Conoscere l'AML - dalla Cattedra alla Corsia"; Hotel Sheraton Parco de' Medici, Via Salvatore Rebecchini, 39 Roma
Relatrice: Sessione Lavori di Gruppo, "Young vs elderly: proposta di algoritmo terapeutico"; 14 novembre, ore 09:30-12:30
- 23-24 novembre 2017
X Corso di Formazione in Ematologia e Oncologia. Come dare più qualità alla vita: la sfida dei nuovi Farmaci in oncologia ed ematologia; Sala delle Culture, Catanzaro
Relatrice: Sessione 1 "La terapia dell'anziano con leucemia acuta Mieloide"; 24 novembre ore 10:00
- 19 dicembre 2017
Advisory Board "L'evoluzione della conoscenza della biologia di malattia e il suo impatto sulle decisioni terapeutiche"; Milano
Relatrice: "Il laboratorio per il paziente MDS basso rischio-RBC-TD oggi", ore 14.30 – 14.45

2018

- 23-24 marzo 2018
9th Investigator Research Meeting; Sheraton Offenbach Hotel Am Büsing Palais Berliner Str.111 Offenbach 63065 Germany

Relatrice: Plenary session 5: Myeloid Disease “Thrombocytopenia in MDS”; 24 marzo, ore 12:20-12:45

- 19-20 aprile 2018
Advanced ITP Discussion-AID project; Hotel Ambasciatori Via Luigi Alamanni 3, Firenze
Relatrice: Sessione Plenaria “Terapia personalizzata per i pazienti affetti da ITP”; 19 aprile 2018 - 17:00-17:40
- 19 maggio 2018
1° FORUM NAZIONALE AIPaSiM-Sindrome Mielodisplastica: Pazienti, Medici e Istituzioni a confronto; Palazzo Lombardia - Auditorium Testori, Milano.
Relatrice: Sessione Tavola Rotonda: I pazienti a confronto. La qualità di vita con la malattia. “Mettere al centro del percorso sanitario la qualità della vita”; ore 14:15-15:10
- 29 maggio 2018
Dall’epigenetica ai nuovi scenari di cura: 10 anni di progressi nelle Neoplasie Mieloidi; Unicredit Pavilion, Piazza Gae Aulenti 10, Milano
Relatrice: III SESSIONE-MDS “Il valore della trasfusione indipendenza e della QoL nelle MDS”; ore 12:25-13:00
- 8-9 giugno 2018
Sindromi mielodisplastiche e leucemie acute: approcci terapeutici a confronto; Palazzo della Provincia di Cosenza, Cosenza
Relatrice: I Sessione - Il Trattamento dei Pazienti a basso rischio - “Il Trattamento del paziente con piastrinopenia Eltrombopag vs Romiplostim”, 8 giugno 2018, ore 17:00-17:30
I Sessione - Il Trattamento dei pazienti ad alto rischio “Ottimizzazione del trattamento con ipometilanti: 5-Azacitidina vs Decitabina, 8 giugno 2018, ore 18:00--18:30
- 29 settembre 2018
QOL-ONE III Annual Conferencfe Sindromi Mielodisplastiche e Complicanze, Consiglio Regionale della Calabria Palazzo Campanella, Reggio Calabria
Relatrice: Sessione MDS: Biologia e clinica- “Nuove terapie delle MDS”, ore 11:10 - 11:35
- 12 ottobre 2018
VIII International Conference “Stem cell trasplantation in MDS and AML treatment; Sheraton Hotel, ul. Bukowska 3-9, Poznań, Polonia
Relatrice: “Treatment of MDS in patients not qualified to stem cell transplantation”
- 12 ottobre 2018
Bridge Educational Meeting; Sheraton Hotel, ul. Bukowska 3-9, Poznań, Polonia
Relatrice: “Azacitidine in older patients with MDS and AML: clinical trial data and case reports”, “Key therapeutic challenges and the clinical benefits of using azacytidine”; ore 10:00-11:00
- 26 ottobre 2018
MDS: Chaos and Order; IRST, Meldola (FC)
Relatrice: II Sessione Diagnosis and Prognosis “Prognostic factors in MDS”; ore 10:50-11:20
- 8 - 9 novembre 2018
Real World Evidence” Nuovi target terapeutici in ematologia”; Auditorium “Fra Agostino Daniele” San Giovanni Rotondo (FG)
Relatrice: Sessione LMA/LLA “La qualità della vita nell’era dei nuovi farmaci in Ematologia”; 9 novembre 2018 ore 12:45-13:15

- 17 novembre 2018
Congresso FISM - Le Sindromi Mielodisplastiche: attualità nell'approccio clinico; Hotel Hilton Garden Inn, Lecce
Relatrice: Sessione La terapia di supporto nelle SMD- "Il trattamento del paziente piastrinopenico grave"; ore 15:20-15:40
- 22-23 novembre 2018
Scientific Stand Alone EPN "10 anni di storia; Hotel Quirinale, Via Nazionale 7 – Roma
Relatrice: Prima sessione: Fisiopatologia generale, inquadramento e workout clinico-PNH: Basi molecolari in EPN ed eziopatogenesi nel contesto MDS e AA; 23 novembre 2018, ore 09:10 -09:30
- 27 novembre 2018
Focus on Cytopenias: update on new advances; Royal Continental Hotel, Napoli
Relatrice: SESSIONE III: APLASTIC ANEMIA- "Other cytopenias (MDS)", 18:00-18:30
- 14 dicembre 2018
AB La diagnosi delle MDS con Sideroblasti ad anello; Starhotels E.C.Ho Viale Andrea Doria, 4 - 20124 Milano
Relatrice: "Probabilità di risposta agli ESA e durata mediana di tale risposta"; ore 15:15-15:45

2019

- 25 gennaio 2019
I Workshop di Ematologia Neoplastica; Foro Italico Umberto I, 22/B Hoteò NH Palermo
Relatrice: "Management (terapia e qualità di vita) del paziente con Sindrome Mielodisplastica ad alto rischio"; ore 10:00-10:30
- 26 gennaio 2019
2° Portuguese Association of Leukemia and Lymphomas (APLL); Porto, Portogallo
Relatrice: Patient participation in clinical trials
- 12-13 aprile 2019
Revolution Ongoing in cytopenia management; Firenze, Palazzo Pucci
Relatrice: Citopenie e tossicità emopoietica del ferro; 13 aprile, ore 11:00-11:30
- 27 settembre 2019
ITP Meeting; Palermo, P.O. V Cervello
Relatrice: La piastrinopenia isolata secondaria a mielodisplasia; ore 12:40-13:00
- 3 ottobre 2019
Focus sul trattamento dell'ITP nell'adulto in Italia, Vicenza, AC Hotel
- 19 ottobre 2019
Le Sindromi Mielodisplastiche: attualità nell'approccio clinico; Hotel NH Catania Parco degli Aragonesi
Relatrice: Sessione La terapia di supporto nelle Sindromi Mielodisplastiche-"Il trattamento del paziente piastrinopenico".
- 25 ottobre 2019
Giornata mondiale delle sindromi mielodisplastiche Incontro FISiM; Firenze
Relatrice: "Terapie attuali e prospettive future nei bassi rischi"; ore 15:15-16:30
- 30 ottobre 2019

Megakaryocytes Academy – Webcast 2 Effects of thrombopoiesis stimulation in ITP, bone marrow failure, and other myeloid disorders; Francoforte, Germania
Relatrice: “Stimulation of the TPO receptor in AML & MDS”

- 7 novembre 2019
Satellite Symposium- Hellenic Society of Hematology 30th National Congress 2019; Atene, Grecia
Relatrice: “An Overview of the current treatment of MDS and future perspectives”
- 14 novembre 2019
Thrombocytopenia: from science to the patient-Portuguese National Meeting; Lisbona, Portogallo
Relatrice: “Síndromes de Falência Medular: passado, presente e futuro”; ore 11:45 -12:30
- 15-16 novembre 2019
Advanced ITP Discussion; Sorrento (NA)
Relatrice: Sessine ITP dalla patofisiologia alla terapia-“Il ruolo degli steroidi in 1° linea: come e per quanto?”; 15 novembre 2019, ore 15:20-15:40

2020

- 21 gennaio 2020
Corso FAD” Focus sulle MDS a basso rischio: dalla diagnosi al trattamento”
Docente: Modulo 4 Gestione del paziente con MDS LR- “Focus sull’anemia nei pazienti con MDS LR e sideroblasti ad anello”
- 18-20 febbraio 2020
Myeloid MATD; Madrid
Relatrice: “MDS QoL Training”; 19 febbraio, ore 14:45-15:45
- 26 marzo 2020
Webinar “Blood and Beyond: Rethinking Blood Use”
Relatrice: Panel: Forward-thinking solutions and policy responses to improve outcome for patients and address the impact of blood transfusion while safeguarding Europe’s blood supply
- 18 giugno 2020
Virtual Meeting
Chairs: Integrating the patients’ voice in hematology - Q&A Panel Discussion Thursday, June 18, 18:00 - 18:45 CEST. In the EHA25 Virtual live Q&A Panel Discussion
- 19 giugno 2020
EHA Guideline kick-off meeting
Consulente: Team Myelodysplastic syndromes
- 14 luglio 2020
Virtual meeting “Impatto della ITP e dei suoi trattamenti sulla QoL del paziente”
Relatrice: 14:45 - 15:05 Overview survey QoL e burden dell’ITP
- 7 settembre 2020
Conference “Clinical and Experimental Hematology 2020”
Relatrice: “Luspatercept – new therapeutic option for MDS patients”

- 9 settembre 2020
Virtual Meeting “MATD (Medical Affairs Training Days)”
Relatrice: “What happens to HRQoL in AML patients?”
- 11 settembre 2020
Virtual Meeting Time is Life: Ravulizumab nella terapia EPN
Relatrice: “Le scale di valutazione della qualità di vita in EPN e i dati dello studio di preferenza di Ravulizumab; ore 16:40
- 22-23-24 settembre 2020
SOHO 2° Italian Conference
Relatrice: “Sessione Myelodysplastic syndromes: State of the art. Relazione: New combinations for treating Higher-risk MDS”; ore 20:00-20:15
- 10 ottobre 2020
Webinar “ITP day”
Relatrice: Fatigue? Un problema sottovalutato
- 22 ottobre 2020
Virtual Meeting “MDS & AML national Workshop”
Relatrice: Luspatercept as a targeted therapy in the treatment of anemia in lower risk MDS
- 19 novembre 2020
Fad sincrona AID 2020 Advanced ITP Discussion
Relatrice: QoL & TPO Mimetici
- 7 dicembre 2020
Webinar “Cancer Bioimmunotherapy in the Covid19 era”
Relatrice: I Sessione: Inflammation Friend or Foes. Canakinumab for the treatment of Covid19-associated pneumonitis

2021

- 06 febbraio 2021
Evento web: Opinions in AML: An Interactive Local Workshop
- 24 febbraio 2021
Tavola Rotonda web “IRON – OFF - Tossicità del ferro e deferasirox in ematologia: informarsi e confrontarsi con un approccio multidisciplinare”
Relatrice: Spotlight on deferasirox: l’impatto sugli outcome clinici nel pz ematologico ore; 15:00 – 16:00
- 08 marzo 2021
Evento web: “Gestione del paziente con early ITP: il ruolo del TPO-RA e l’importanza della remissione”
Relatrice: “La gestione dell’early ITP nella real life e qualità di vita del paziente” ore: 17:15-18:15

- 24 marzo 2021
Evento web: "BMS HRQoL MATD"
Relatrice: "How to evaluate the results of HRQoL tools" ore: 15:20 – 15:40.
- 21 aprile 2021
TPO-ra IN EMATOLOGIA NUOVE FRONTIERE NELL'MDS
Relatrice "Terapie della piastrinopenia nelle MDS1", ore: 16.00 – 16.20
- 26-27 aprile 2021
AIL/LEUKEMIA 2021
Relatrice: "Relevance of quality of life and patient reported outcome in designing therapeutic strategies in MDS" ore 14:30 – 14:45
- 26 maggio 2021
Advisory Board Novartis "Sindromi Mielodisplastiche (MDS) - stato dell'arte e nuove prospettive terapeutiche"
Ruolo: Advisor. Ore: 14:00 – 17:00
- 14 giugno 2021
Rethinking blood use
Ore: 12:00 – 13:00
- 15 giugno 2021
Chair: Live Q&A Session of the oral abstract session on "Patient's voice and health outcomes in hematology" at the EHA2021 Virtual Congress (June 9-17, 2021)
- 17 giugno 2021
Tavola Rotonda Virtuale "Conversations from the Clinic How Do I Maintain Remission in AML"
Relatrice: Potential approaches to extend remission in patients with AML
- 24 – 26 giugno 2021
MASCC/ISOO Annual Meeting 2021: Seville, Spain
Relatrice: Patient-Reported Outcome Measurement (PROMs) in patients with hematological malignancies. Should we measure different PROMs in older versus younger adults with cancer? 26 giugno 2021 ore: 14:00 – 15:00 virtuale
- 01 luglio 2021
Emagination
Relatrice: "Stato dell'arte, terapie attuali, unmet needs (ESA) e nuovo presente del trattamento dell'anemia nelle MDS-LR con RS"
Registrazione evento: 10:00 – 13:00

- 08 luglio 2021
Advisory Board: “Novartis - Sabatolimab Virtual”
Consulting Services
- 09 luglio 2021
Revolade “Accelerate” Internal Trainings
Relatrice: training Accelerate Expertise Internal Training Module 12: “Eltrombopag: + ten years of experience in the ITP management” ore 16:00
- 16 settembre 2021
Anniversary Revolution
Relatrice “Come il covid ha cambiato lo scenario” ore 16:45 – 17:40
- 23 settembre 2021
Evento web “- LA GESTIONE A LUNGO TERMINE DEL PAZIENTE CON EPN
La salute del paziente in terapia ed il mantenimento della qualità di vita”
17.10-17.30.
Relatrice: “La salute del paziente e qualità di vita in corso di terapia: elementi per mantenere aderenza.” Ore 17.10-17.30.
- 05 ottobre 2021
Evento “Diagnosi e trattamento delle MDS a basso rischio”
Moderatrice: sessione I ore: 14:10 – 15:10
- 06 ottobre 2021
Advisory Board “Luspatercept”
Servizi di advice and counsel
- 07 ottobre 2021
EHA SWG Aging and Hematology
Relatrice: “PROMs in hematological malignancies”
- 13 ottobre 2021
XVI Incontro Annuale: La malattia di Gaucher
Relatrice: “Applicazione di un PROM specific per la malattia di Gaucher”
- 24/27 ottobre 2021
48° Congresso Nazionale SIE e 16° Congresso Nazionale – Milano
Moderatrice. delle comunicazioni orali SIE “Sindromi Mielodisplastiche”
- 05 novembre 2021
Janssen MDS Advisory Board meeting
Consultant: Provide input on the clinical development program and protocol for TPOM:

Ore: 13:00 / 15.00

- 06 novembre 2021
SIOG 2021 Annual Conference
Relatrice: Session title: “MDT Haematology/Lymphoma - Patient-reported outcome measurements (PROMs) in older adults with haematological malignancies”
Presentation title: PROMs in MDS
- 12 novembre 2021
Evento: Emagination
Relatrice: Exploring new Horizons in MDS – from pivotal trial to clinical practice
Ora: 16:20 – 17:00
- 09 e 22 novembre 2021
Novartis Meet the Expert in HR-MDS
Relatrice: Key remaining unmet needs in higher-risk MDS: Case study of a patient ineligible for HSCT; Overview of new agents in development for the treatment of higher-risk MDS
- 15 novembre 2021
EHA-PTHiT Mini Hematology Tutorial
Lezione/relatrice: sessione “A new set of treatment options for low-risk myelodysplastic syndrome”,
Relazione/Lettura: “Advances in the Treatment of Patients with Low-Risk MDS”. Ore: 18:45 – 20:00. Virtuale
- 16 novembre 2021
Evento: “ACCELERATE INTERNAL TRAINING How does Eltrombopag satisfy patient’s and clinician’s needs in the ITP management?”
Relatrice: 2Eltrombopag, an experience 10 years long for a better management of ITP
Treatment with Eltrombopag: a clinical case - “Q&A”- Re-run of presentation for filming purposes”
- 19 novembre 2021
Congresso: Focuson Cytopenias: update on new advances 2.0 – Napoli
SESSIONE III - APLASTIC ANEMIA
Relatrice: Lettura: “Other Cytopenias”, ore 15.15-15.45
- 20 novembre 2021
Congresso: “ADVANCED ITP DISCUSSION – AID” - Roma
Relatrice: Patient Reported Outcomes: qualità di vita e sintomi da paziente con ITP. Ora: 10:45 – 11:00.
- 16/17 dicembre 2021
Congresso: Stand-alone Ultomiris
Relatrice: 17 dicembre 2021 orario 12:40 – 13:40
La gestione del pz con EPN in corso di complicanze infettive

2022

- 18/19 marzo 2022

Hybrid EHA-SLCH Hematology Tutorial 2022

Relazione/Lettura: "Risk stratification and management of high risk MDS" 18 marzo 2022 Ore: 10:30 – 12:00. Virtuale

- 10 giugno 2022
Chair: session on "Quality of life and symptoms: Evidence based patient-reported outcomes in clinical decision-making at the EHA2022 Hybrid Congress (June 9-12, 2022)
- 11 giugno 2022
Chair: session on "Quality of life and health economics in hematological patients" at the EHA2022 Hybrid Congress (June 9-12, 2022)
- 26 settembre 2022
Congresso SIE, Roma
Moderatrice delle "COMUNICAZIONI ORALI - Anemie e sindromi mielodisplastiche", dalle ore 11:50 alle ore 13:20,
- 01 ottobre 2022
7° ITP PATIENT'S DAY, Milano
Relatrice: "La qualità della vita dei pazienti con ITP, quali soluzioni per migliorarla?" Dalle ore 11:40 alle ore 12:15.
- 11 ottobre 2022
Congresso Attualità e Prospettive in Ematologia 2022, Palermo
Relatrice: "Trattamento della MDS ad alto rischio." Dalle ore 10:50 alle ore 11:10.
- 23-26 ottobre 2022
SOHO ITALY 4th ITALIAN CONFERENCE, Roma
Relatrice: "Treatment of Lower Risk MDS" Dalle ore 12:30 alle ore 12:45.
- 25 ottobre 2022, Roma
I pazienti con neoplasia del sangue e la loro qualità della vita: QoL, un modello innovativo di comprensione e di intervento.
Relatrice: "La trasformazione della voce del paziente in dati misurabili". Dalle ore 16:00 alle ore 16:15.
- 4-5 novembre 2022, Sorrento
ITP CAMP 2022 IV Edizione
Relatrice: "Piastrinopenie secondarie". Dalle ore 9:15 alle ore 10:00.
- 26 novembre 2022, Cagliari
FORUM I PAZIENTI INCONTRANO I MEDICI
Relatrice: "Qualità di vita: come si misura". Dalle ore 11:55 alle ore 12:15.
- 29 novembre 2022 Virtuale

BMS WW/Celgene: Surrogate Endpoints Advisory Board

- 8 dicembre 2023, New Orleans
WW Medical MDS ASH Advisory Board Meeting
- 13 dicembre 2023, New Orleans
Daiichi Sankyo Global Quizartinib Medical Advisory Board
- 27 gennaio 2023 Milano
INC3PTION - Per le persone con l'EPN inizia una nuova storia
Relatrice: "Qualità della vita". Dalle 14:15 alle 14:45.
- 30 gennaio 2023 Roma
BMS Ad B luspatercept nelle sindromi mielodisplastiche

**Presentazioni a
Congressi Abstract e
Poster**

1992

Romeo M, **Oliva EN**, Panuccio V, Zoccali C (1992). **Incidenza dell'insufficienza renale cronica in un'area meridionale di 40.000 abitanti.** In: 33°Congresso della Società Italiana di Nefrologia; GIORNALE ITALIANO DI NEFROLOGIA vol. 9, ISSN: 0393-5590; Roma, 19-22 Maggio 1992

1993

- L'Abbate A, **Oliva EN**, Martorano C, Postorino M, Delfino D (1993). **Trattamento a lungo termine della nefrite lupica severa con ciclosporina.** In: 34°Congresso della Società Italiana di Nefrologia; GIORNALE ITALIANO DI NEFROLOGIA, vol. 10, ISSN: 0393-5590
- **Oliva EN**, Panuccio V, Romeo M, Zoccali C (1994). **Il riferimento tardivo dei pazienti uremici ai centri di nefrologia-dialisi. Un problema da focalizzare.** In: 35°Congresso della Società Italiana di Nefrologia; GIORNALE ITALIANO DI NEFROLOGIA ISSN: 0393-5590; Bari, 18-21 Maggio 1994

1994

- L'Abbate A, Cutrupi S, **Oliva EN**, Rognetta M (1994). **Glomerulonefrite crioglobulinemica: trattamento sincronizzato con ciclofosfamide e plasmaferesi.** In: 35°Congresso della Società Italiana di Nefrologia. GIORNALE ITALIANO DI NEFROLOGIA, ISSN: 0393-5590; Bari, 18-21 Maggio 1994
- Romeo M, **Oliva EN**, Panuccio V, Marino C, Zoccali C (1994). **Incidenza dell'insufficienza renale cronica in un'area dell'Italia meridionale di 573.093 abitanti.** In: 35°Congresso della Società Italiana di Nefrologia; GIORNALE ITALIANO DI NEFROLOGIA vol. 11, p. 117-122, ISSN: 0393-5590; Bari, 18-21 Maggio 1994

1995

- L'Abbate A, Cutrupi S, **Oliva EN**, Maggi F, Vatteroni M, Bendinelli M, Pistello M (1995). **Chronic hepatitis C virus infections in dialysis: relevance of ANTI-HCV IgM antibodies.** In: 32° Congresso ERA-EDTA; NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 10 ISSN: 0931-0509; Atene
- L'Abbate A, Cutrupi S, **Oliva EN**, Maggi F, Vatteroni M (1995). **Anticorpi IgM anti-HCV nei pazienti in dialisi con epatite cronica.** In: 36° Congresso della Società Italiana di Nefrologia; GIORNALE ITALIANO DI NEFROLOGIA, vol. 12, ISSN: 0393-5590; Genova, 17-20 Maggio 1995

1996

- **Oliva EN**, Martino B, Postorino M, Ronco F, Zoccali C (1996). **L'eritrocitosi puo' causare insufficienza renale?.** In: 37 Congresso della Società Italiana di Nefrologia. GIORNALE ITALIANO DI NEFROLOGIA, ISSN: 0393-5590,; Cagliari, 29 Maggio-1 Giugno 1996

1997

- **Oliva EN**, Valvo E, Russo D, Minutolo R, Panichi V, De Pietro S, Zuccala' A, Zucchelli P, Zoccali C (1997). **Il Losartan potenzia l'effetto antiproteinurico degli ACE-inibitori nei pazienti con nefropatie croniche.** In: 38° Congresso Nazionale della Società Italiana di Nefrologia. Giornale Italiano di Nefrologia, ISSN: 0393-5590; 23-27 Giugno 1997

2001

- Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, **Oliva EN**, Schiavone EM, Pollio F, Palmieri S, Gianfaldoni G, Leoni F (2001) **Aggressive Salvage Treatment Is Not Appropriate or The Majority Of Elderly Patients With Acute Myeloid Leukemia Relapsed From First Complete Remission.** In: 6th EHA Congress; Haematologica January 2001 86: 814-820 ISSN: 1592-8721, Francoforte , Germania, 21-24 June 2001

2002

- Panuccio V, **Oliva EN**, Parlongo S, Cutrupi S, Catalano F, Tripepi G, Zoccali C. (2002). **La cistatina e' un affidabile marker del filtrato glomerulare nella sindrome nefrosica.** In: 43° Congresso Nazionale della Società Italiana di Nefrologia. Giornale Italiano di Nefrologia vol. S20, ISSN: 0393-5590; Firenze, 22-25 Maggio 2002

2004

- **Oliva EN**, Borislav DD, D'Angelo A, Benedetto F, Nobile F (2004) **Hemoglobin Level Threshold in Myelodysplastic Syndrome: Cardiac Hypertrophy and Quality of Life.** In: 46th ASH Annual Meeting; Blood (2004) 104 (11): 1444. <https://doi.org/10.1182/blood.V104.11.1444.1444>

2006

- **Oliva EN**, Latagliata R, Danbova M, Vincelli I, Rovati B, Ronco F, Carmosino I, Specchia G, Breccia M, Impera S, Attolico I, Nobile F (2006) **Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life**. In: 48th ASH Annual Meeting; Blood 2006 108(11)2667. December 09 - 12, 2006; Orlando, Florida
- **Oliva EN**, Benedetto F, Specchia G, Vincelli I, Colonna P, Liso V, Fortugno F, Nobile F (2006) **Treatment of Anemia of Myelodysplastic Syndromes and Improvements in Cardiac Geometry**. Blood 2006 108:4837. December 09 - 12, 2006; Orlando, Florida NON SELEZIONATO PER PRESENTAZIONE

2008

- Sortino GS, Milone GM, Leotta GL, Poidomani M, Di Marco A, **Oliva EN**, Spadaro A, Marturano E, Azzaro MP, Coppoletta S (2008) **Use of KGF (Palifermin) but not of G-CSF is associated to a reduced rate of infections after high dose chemotherapy and autologous PBSC transplantation**. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation. Firenze, 30 marzo-2 aprile 2008. October 2007. Haematologica, Volume: 9, 567-568
- **Oliva EN**, Latagliata R, Specchia G, Ronco F, Alimena G, Pastore D, Impera S, Guglielmo P, Carmosino I, Vincelli I, Alati C, Breccia M, Napoleone L, Nobile F (2008) **Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients**. In: 50th ASH Annual Meeting; Blood 2008 112:1949 ISSN: 1528-0020; San Francisco (California) USA, 6-9 December 2008
- **Oliva EN**, Clissa C, Santini V, Poloni A, Liso V, Cilloni D, Terenzi A, Impera S, Levis A, Cortelezzi A, Ghio R, Semenzato G, Villani O, Aloe Spiriti MA (2008). **Quality of Life Assessment in Patients Affected by Myelodysplastic Syndrome**. In: 50th ASH Annual Meeting; Blood 2008; 112: 2363 ISSN: 1528-0020; San Francisco (California) USA, 6-9 December 2008
- Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Tatarelli C, Lunghi M, Fili C, Orciuolo E, Ciuffreda L, Vigna E, Della Cioppa P, Candoni A, Ferrero D, Palmieri S, Palumbo G, Di Renzo N, **Oliva EN**, Sanpaolo G, Pastore D, Tonso A, Santagostino A, Rocco S, Villani O, D'Auria F, D'Arco AM, Gaidano G, Galimberti S, Russo D, Venditti A, Aloe Spiriti MA; Leone G, Santini V (2008) **5 Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program**. In: 50th ASH Annual Meeting; Blood 2008 112:2680 ISSN: 1528-0020; San Francisco (California) USA, 6-9 December 2008

2009

- **Oliva EN**, Cuzzola M, Iacopino P, Alimena G, Cannella L, Morabito F, Galimberti S, Ghio R, Poloni A, Specchia G, Laganà C, D'Errigo MG, Alati C, Modafferi B, Cortelezzi A, Nobile F (2009) **Gene expression patterns in MDS with del5q before and during lenalidomide treatment**. MDS International Symposium, Patrasco, Grecia, Maggio 2009. Leuk Res, supplement, 2009.
- Finelli C, Aloe Spiriti MA, Santini V, Poloni A, Liso V, Cilloni D, Terenzi A, Impera S, Levis

A, Cortelezzi A, Ghio R, Musto P, Semenzato G, **Oliva EN** (2009). **Changes in quality of life and patient-physician communication in myelodysplastic syndrome**. SIE 2009. Haematologica, 2009, v 94, suppl. 4, pp 25-26

- **Oliva EN**, Santini V, Poloni A, Liso V, Cilloni D, Terenzi A, Guglielmo P, Ghio R, Cortelezzi A, Semenzato G, Clissa C, Salci F, Villani O, Aloe Spiriti MA (2009). **Quality of Life in Myelodysplastic Syndromes and Physicians' Perception**. In: 51th ASH Annual Meeting; Blood 2009 114:3822 SSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 December 2009 <https://doi.org/10.1182/blood.V114.22.3822.3822>
- **Oliva EN**, Latagliata R, Morabito F, Poloni A, Ghio R, Cortelezzi A, Finelli C, Baratè C, Ronco F, Aloe Spiriti MA, Ricco A, Breccia M, Alati C, Praticò G, Nobile F (2009) **Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study**. In: 51th ASH Annual Meeting; Blood 2009 114:2763 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 December 2009 <https://doi.org/10.1182/blood.V114.22.2763.2763>
- **Oliva EN**; Cuzzola M, Latagliata R, Ronco F, D'Errigo MG, Morabito F, Galimberti S, Balleari E, Specchia G, Cortelezzi A, Poloni A, Finelli C, Alimena G, Iacopino P, Laganà C, Mendicino F, Rodà F, Nobile F (2009) **Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment**. In: 51th ASH Annual Meeting; Blood 2009 114:2622 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 December 2009
- **Oliva EN**; Gugliotta L, Cantonetti M, Piccin A, Mazzucconi MG, Candoni A, Cacciola RR, Cacciola E, Lunghi M, Tura S (2009). **Quality of Life in Elderly Patients with Essential Thrombocythemia**. In: 51th ASH Annual Meeting; Blood 2009 114:4973; ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 December 2009

2010

- **Oliva EN**, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, Latagliata R (2011). **Quality Of Life in Elderly Patients with Acute Myeloid Leukemia: Patients May Be More Accurate Than Physicians**. In: 16th EHA Congress; Haematologica May 2011 96: 696-702; Doi:10.3324/haematol.2010.036715 ISSN: 1592-8721; London, UK, 9-12 June 2011
- **Oliva EN**, Nobile F, Ronco F, Alati C, Morabito F, Poloni A, Cortelezzi A, Aloe Spiriti MA, Ricco A, Volpe A, Balleari E, Sanpaolo G, Breccia M, Clissa C, Alimena G, Latagliata R (2010) **Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)**. In: 52th ASH Annual Meeting, Blood 2010 116:2927 ISSN: 1528-0020, Orlando (Florida) USA, 4-7 December 2010
- **Oliva EN**, Nobile F, Iacopino P, Alimena G, Di Raimondo F, Palumbo GA, Laganà C, D'Errico MG, Latagliata R, Cuzzola M (2010) **Increases in Mirna-145 and Mirna-146a Expression in Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide**. In: 52th ASH Annual Meeting. Blood 2010 116:3631 ISSN: 1528-0020; Orlando (Florida) USA, 4-7 December 2010 <https://doi.org/10.1182/blood.V116.21.3631.3631>
- Vincelli I, **Oliva EN**, Ronco F, Cufari P, Oliva BM, Gatto V, Laganà C, D'Errigo MG, Nobile F

(2010) **Primary Immune Thrombocytopenia (ITP) Guidelines for Bone Marrow Aspirate Reduce the Diagnostic Rate of Myelodysplastic Syndromes.** In: 52th ASH Annual Meeting. Blood 2010 116:4974; ISSN: 1528-0020, Orlando (Florida) USA, 4-7 December 2010

2011

- von Mackensen S, Germing U, Götze K, Giagounidis A, **Oliva EN** (2011) **Quality of Life Assessment by QOL-E, an MDS-specific tool, in German patients with Myelodysplastic Syndromes.** In the 16th Congress of the European Hematology Association Abstr. no.: 1968
- Voso MT, Fianchi L, Criscuolo M, Levis A, Finelli C, Musto P, Maurillo L, **Oliva EN**, Greco M, Pagano L, Leone G (2011) **Efficacy of 5-Azacytidine in the treatment of therapy-related malignant neoplasms (t-MN).** Abstract May 2011. Leukemia Research 35 DOI:10.1016/S0145-2126(11)70194-1
- **Oliva EN**, latagliata R, Aloe Spiriti MA, Cortelezzi A, Balleari E, Poloni A, Sanpaolo G, Finelli C, Volpe A, Ricco A, Palumbo G, Baratè C, Ronco F, Morabito F, Alati C, Breccia M, Alimena G, Nobile F (2011) **Clinically meaningful responses in low risk MDS patients with del5q treated with lenalidomide: Quality of life and cardiac changes.** Leukemia Research 35 (2011) S27-S142. of the 11th International Symposium on Myelodysplastic Syndromes (MDS), 18-21 May 2011, Edinburgh, UK
- Cuzzola M, Latagliata R, Aloe Spiriti MA, Nobile F, Cortelezzi A, Finelli C, Sanpaolo G, Palumbo G, Breccia M, Di Raimondo F, Alimena G, **Oliva EN** (2011). **MicroRNA changes in patients with IPSS lower-risk myelodysplastic syndromes and del5q undergoing treatment with lenalidomide.** Leukemia Research, Volume 35, Supplement 1, May 2011, Page S15. Abstract of the 11th International Symposium on Myelodysplastic Syndromes (MDS), 18-21 May 2011, Edinburgh, UK
- Fang J, Bolanos L; Rhyasen G, Rigolino C, Cortelezzi A, **Oliva EN**, Cuzzola M, Starczynowski DT (2011) **Degradation of TRAF6 by Bortezomib-Induced Autophagy Contributes to Cell Death in Acute Myeloid Leukemia and Myelodysplastic Syndrome.** In: 53 th ASH Annual Meeting. Blood 2011 118:2452 ISSN: 1528-0020; San Diego (California) USA, 10-13 December 2011
- Rhyasen G, Bolanos L, Fang J, Rigolino C, Cortelezzi A, **Oliva EN**, Cuzzola M, Starczynowski DT (2011) **Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.** In: 53 th ASH Annual Meeting. Blood 2011 118:612 ISSN: 1528-0020; San Diego (California) USA, 10-13 December 2011

2012

- **Oliva EN**; Santini V, Zini G, Palumbo GA, Poloni A, Cortelezzi A, Voso MT, Molteni A, Sanpaolo G, Marino A, Rodà F, Alati C, Ronco F, Di Raimondo F, Leoni P, Alimena G, Finotto S, Latagliata R, Nobile F (2012). **Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS).** In: 54 th ASH Annual Meeting. BLOOD, vol. 120:923, ISSN: 1528-0020, Atlanta (Georgia) USA, 9-12 December 2012
- Vincelli I, Cufari P, Rodà F, D'Errigo MG, **Oliva EN**, Nobile F (2012) **Primary Immune**

Thrombocytopenia Guidelines for Bone Marrow Aspirate Reduce the Diagnostic Rate of Myelodysplastic Syndromes. In: 54 th ASH Annual Meeting; Blood 2012 120:3328 SSN: 1528-0020; Atlanta (Georgia) USA, 9-12 December 2012

- **Oliva EN**, Albano F, Di Renzo N, Pavone V, Molica S, Morabito F, Guarini A, Tarantini G, Capalbo S, Iannitto E, Quarta G, Cascavilla N, Tassone P, Iuliano F, Porciello R, Casieri P, Laganà C, Nobile F, Specchia G (2012) **Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy.** In: 54 th ASH Annual Meeting; Blood 2012 120:50623; Atlanta (Georgia) USA, 9-12 December 2012

2013

- **Oliva EN**, Santini V, Zini G, Palumbo G, Poloni A, Cortelezzi A, Rodeghiero F, Voso MT, Molteni A, Sanpaolo G, Liberati A, Morabito F, Balleari E, Impera S, Salvi F, Aloe Spiriti MA, Marino A, Rodà F, Alati C, Ronco F, Di Raimondo F, Leoni P, Alimena G, Fioritoni G, Latagliata R, Nobile F (2013). **Eltrombopag for the treatment of Low and Intermediate -1 IPSS Risk Myelodysplastic Syndromes: results of a prospective, randomized, trial.** In: 18th EHA Congress; Haematologica June 2013 98: (s1); Stoccolma, Svezia, 13-16 June 2013
- **Oliva EN**, Santarone S, Leoni P, Alati C, Volpe A, Cascavilla N, Candoni A, Musto P, Morabito F, Di Raimondo F, Cufari P, Santacaterina I, Vincelli I, Capelli D, Freyrie A, Salutati P, Di Bartolomeo P, Martino B, Ronco F, Cortelezzi A (2013). **A Randomized Open-Label Study to Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE).** In: 55th ASH Annual Meeting; Blood 2013 122:3967 ISSN: 1528-0020; New Orleans (Louisiana)USA, 7-10 December 2013
- Messa E, Gioia DM, Masiera E, Allione B, Angelucci E, Balleari E, Bonferroni M, Cametti G, Centurioni R, Crisà E, Cilloni D, Danise P, Del Corso L, Ferrero D, Finelli C, Freilone R, Gaidano G, Lunghi M, Musto P; **Oliva EN**, Pappano S, Plezzari AM, Poloni A, Santini V, Salvi F, Tassara R, Visani G, saglio G, Levis A (2013). **A RealLife Survey on Erythropoietin Alpha Treatment in a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study.** In: 55th ASH Annual Meeting; Blood 2013 122:745 ISSN: 1528-0020; New Orleans (Louisiana) USA, 7-10 December 2013
- Pepe A, Meloni A, Carulli G, **Oliva EN**, Arcioni F, Storti S, Grassedonio E, Renne S, Missere M, Positano V, Lombardi M, Rizzo M (2013). **Myocardial Tissue Characterization by Cardiac MR Imaging In Myelodysplastic Syndromes.** In: 55th ASH Annual Meeting; Blood 2013 122:5211 ISSN: 1528-0020; New Orleans (Louisiana)USA, 7-10 December 2013
- Pepe A, Meloni A, Carulli G, **Oliva EN**, Arcioni F, Storti S, Toia P, Renne S, Restaino G, Salvatori C, Lombardi M, Rizzo M (2013) **MRI Survey in Transfusion-Dependent and Non-Transfusion-Dependent MDS Patients.** In: 55th ASH Annual Meeting; Blood 2013 122:2819; New Orleans (Louisiana)USA, 7-10 December 2013

2014

- Pepe A, Meloni A, Carulli G, **Oliva EN**, Arcioni F, Storti S, Neri MG, Grassedonio E, Renne S, Restaino G, Salvatori C, Positano V, Rizzo M (2014) **Prospective Changes of Cardiac and Hepatic Iron and Cardiac Function in Low and Intermediate-1 Risk MDS**

Patients. In: 56th ASH Annual Meeting; Blood 2014 124:191 ISSN: 1528-0020; San Francisco (California) USA, 6-9 December 2014

- Marino AG, **Oliva EN**, Oliva BM, Sofo G, Ranieri N, Ronco F (2014). **Usefulness of Screening for Paroxysmal Nocturnal Hemoglobinuria in Patients with Undefined Anemia.** In: 56th ASH Annual Meeting; Blood 2014 124:5161 ISSN: 0006-4971; San Francisco (California) USA, 6-9 December 2014
- Salek S, **Oliva EN**, Ionova T, Klaassen R, Fedorenko D, Waldmann A (2014) **Translating Patient-Reported Outcomes into Decision-Making in Malignant Hematology.** Abstract. In the 21st Annual Conference ISOQOL
- Pepe A, Meloni G, Carulli G, **Oliva EN**, Arcioni F, Storti S, Grassedonio E, Renne S, Missere M, Positano V, Rizzo M (2014) **Myocardial Tissue Characterization by Cardiac MR Imaging in Myelodysplastic Syndromes.** In the Euro CMR 2014 12th Annual Meeting of the Cardiovascular Magnetic Resonance Section of the European Association of Cardiovascular Imaging, May 15–17, 2014, Palais Niederoesterreich, Vienna, Austria. Eur Heart J Cardiovascular Imaging Abstract Supplement, May 2014,1107(pp48)
- Pepe, A, Meloni A, Carulli G, **Oliva EN**, Arcioni F, Fraticelli V, Toia P, Renne S, Restaino G, Salvatori C, Rizzo M (2014) **MRI Survey in Transfusion-Dependent and Non-Transfusion-Dependent MDS Patients.** In the Euro CMR 2014 12th Annual Meeting of the Cardiovascular Magnetic Resonance Section of the European Association of Cardiovascular Imaging, May 15–17, 2014, Palais Niederoesterreich, Vienna, Austria. Eur Heart J Cardiovascular Imaging Abstract Supplement, May 2014, 1108 (pp18)
- **Oliva EN**, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo G, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, Santacaterina I, Kündgen A, Germing U, Latagliata R (2014) **Clinical Benefit of Lenalidomide Treatment for Low and Intermediate -1 IPSS Risk Myelodysplastic Syndromes with Del(5q) before Transfusion Dependence.** In: 19th EHA Congress; S1331; 99(s1) Haematologica June 2014. Milan, Italy June 12-15 2014
- **Oliva EN**, Alati C, Salutari P, Freyrie A, Candoni A, Simeone E, Ventura G, Cortelezzi A, Capelli D, Leoni P, Di Bartolomeo P, Marino AG, Cufari P, Di Raimondo F, Mauro E, Volpe A, Cascavilla N, Musto P, Morabito F, Niscola P, Specchia G, Ronco F (2014) **Azacitidine As Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia Significantly Prolongs Disease-Free Survival: Interim Results from a Prospective, Randomized, Open-Label, Phase III Multicenter Trial.** In: 56th ASH Annual Meeting Blood (2014) 124 (21): 2299. <https://doi.org/10.1182/blood.V124.21.2299.2299> San Francisco (California) USA, 6-9 December 2014
- Fang J, Liu X, Bolanos L, Barker B, Rigolino, Cortelezzi A, **Oliva EN**, MacBeth KJ, Komurov K, Starczynowski DT (2014). **A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes.** In: 56th ASH Annual Meeting; Blood 2014 124:1898 ISSN :1528-0020; <https://doi.org/10.1182/blood.V124.21.1898.1898> San Francisco (California) USA, 6-9 December 2014
- Martino B, Mammì C, Labate C, Martino EA, Ronco F, Recchia AG, Ielo D, Alati C, **Oliva**

EN, Laganà C, Morabito F (2014). **On the Absence of Calreticulin (CALR) Mutations in Chronic Myeloproliferative Neoplasms (MPNs) with Splanchnic Venous Thrombosis (SVT): Experience from a Single Institution.** In: 56th ASH Annual Meeting; Blood (2014) 124 (21): 3198. San Francisco (California) USA, 6-9 December 2014. 634. MYELOPROLIFERATIVE SYNDROMES: CLINICAL: POSTER II, DECEMBER 6, 2014 <https://doi.org/10.1182/blood.V124.21.3198.3198>

2015

- Meloni A, Rizzo M, Carulli G, **Oliva EN**, Arcioni F, Storti S, Neri MG, Renne S, Grassedonio E, Restaino G, Positano V, Pepe A (2015) **Prospective Changes of Cardiac and Hepatic Iron and Cardiac Function in Low and Intermediate-1 Risk MDS Patients.** In: 23th ISMRM International Society for Magnetic Resonance in Medicine. Proc. Intl. Soc. Mag. Reason. Med. 23 (2015) 2631
- **Oliva EN**, Santini V, Alati C, Sanpaolo G, Poloni A, Molteni A, Ronco F, Palumbo G, marino A, Impera S, Balleari E, Salutari P, Cufari P, Santacaterina I, Avanzini P, Niscola P, Liberati AM, Ricco A, Morabito F, Cortelezzi A, Fianchi L, Buccisano F, Fenaux P, Beyne-Rauzy B, Rodeghiero F, Salvi F, Latagliata R (2015). **Quality of life in patients with lower risk Myelodysplastic Syndromes with severe thrombocytopenia treated with eltrombopag: Interim results of a randomized, placebo controlled prospective trial.** In: 20th EHA Congress; Haematologica vol. 100 ISSN: 0390-6078; Vienna, Austria, 11-14 June 2015
- **Oliva EN**, Santini V, Alati C, Poloni A, Molteni A, Niscola P, Sanpaolo G, Salvi F, Palumbo GA, Balleari E, Impera S, Cortelezzi A, Liberati AM, Avanzini P, Di Bartolomeo P, Rose C, Beyne-Rauzy O, Buccisano F, Bocchia M, Morabito F, Stamatoullas A, Ronco F, Zini G, D'Errico MG, Ranieri N, Cufari P, Santacaterina I, Fenaux P, Latagliata R (2015). **Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial.** In: 57th ASH Annual Meeting; Blood 2015 126:91 ISSN: 1528-0020, Orlando (Florida) USA, 5 -8 December 2015
- Vitrano A, Calvaruso G, Tesè L, Gioia F, Cassarà F, Campisi S, Butera F, Commendatore V, Rizzo M, Santoro V, Cigna V, Quota A, Bagnato S, Argento C, Fidone C, Schembari D, Gerardi C, Barbiera F, Bellissima G, Giugno G, Polizzi G, Rosso R, Abbate G, Caruso V, Chiodi E, Gamberini MR, Giorgi B, Putti MC, DE Ritis MR, Filosa A, **Oliva EN**, Arcadi N, Sacco M, Di Maggio R, Mistretta L, Di Salco V, Giangreco A, Maggio A (2015). **Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies.** In: 57th ASH Annual Meeting; Blood 2015 126:2146 ISSN: 1528-0020; Orlando (Florida) USA, 5 -8 December 2015
- **Oliva EN**, Salutari P, Candoni A, Freyrie A, Capelli D, Di Raimondo F, Volpe A, Cascavilla N, Di Bartolomeo P, Simeone E, Cortelezzi A, Leoni P, Musto P, Morabito F, Niscola P, Ranieri N, Santacaterina I, Marino AG, Cufari P, Alati C, Ronco F (2015) **Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy.** In: 57th ASH Annual Meeting; Blood 2015 126:2120 ISSN: 1528-0020; Orlando (Florida) USA, 5 -8 December 2015
- Prebet T, Cluzeau T, Par S, Germing U, Ades L, Platzbecker U, Vey N, Goetze K, Kelaidi C,

Oliva EN, Al Ali NH, Fenaux P, Gore DS, Komrokji RS (2015) Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy. In: 57th ASH Annual Meeting; Blood 2015 126:95 ISSN: 1528-0020, Orlando (Florida) USA, 5 -8 December 2015

2016

- Salek S, **Oliva EN**, Ionova T (2016) **Quality of Life in patients with haematological malignancies.** Onco clinical Hematology. volume 9 number 3, pp 361-362. In: IV Eurasian Hematology Forum. March, 2016; Saint Petersburg.
- Fenaux P, Santini V, Aloe Spiriti MA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, **Oliva EN**, Symeonidis A, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U (2016). **Randomized, double-blind, placebo- controlled, multicenter study evaluating epoetin alfa versus placebo in anemic patient with IPSS Low -Int 1 risk MDS.** In: 21th EHA Congress; Haematologica 101(suppl.1): 71, abstr:p248, 2016 ISSN: 0390-6078; Copenhagen, Danimarca, 9-12 June 2016
- Platzbecker U, Symeonidis A, **Oliva EN**, Goede JS, Delforge M, Mayer J, Badre S, Gasal E, Mehta B, Franklin J (2016) **Arcade (20090160): A phase 3 randomized placebo-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patient with low or intermediate -1 risk myelodysplastic syndromes (MDS).** In: 21th EHA Congress; Haematologica 101(suppl.1): 15, abstract S128 ISSN: 0390-6078; Copenhagen, Danimarca, 9-12 June 2016
- Salek S, Goswami P, Else R, **Oliva EN**, Ionova T (2016) **The impact of hematological malignancy on patients' health-related quality of life and symptoms: A qualitative study.** In: 21th EHA Congress; Haematologica. 2016; Vol. 101 (Suppl. 1): 598; Copenhagen, Denmark, 9-12 June 2016
- Cuzzola M, Alati C, Di Bartolomeo P, Salutati P, Candoni A, Simeone E, Cortelezzi A, Freyrie A, Di Raimondo F, Calafiore V, Niscola P, Capelli D, Irrera G, Rigolino C, Cannatà MC, Marino A, De Angelis A, Ronco F, **Oliva EN** (2016) **Biological markers of relapse in elderly patients with AML in CR after induction -consolidation chemotherapy and maintenance with 5-Azacitidine.** In: 21th EHA Congress; EHA Library. Cuzzola M. Jun 9, 2016; 132455; E906. Copenhagen, Denmark, 9-12 June 2016
- Balleari E, Filiberti R, Salvetti C, Allione B, Angelucci E, Calzamiglia T, Cavaliere M, Cilloni D, Clavio M, Da Col A, Danise P, Di Tucci AA, Ferrero D, Finelli C, Gioia D, Lemoli RM, Çevis A, Messa E, Masera E, Miglino M, Musto P, **Oliva EN**, Poloni A, Scudeletti M, Tassara R, Santini V (2016) **Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodysplastic Syndromes (FISM).** In: 58th ASH Annual Meeting; Blood 2016 128:4342 ISSN: 1528-0020; San Diego (California) USA, 3-6 December 2016
- Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama, B, Badre S,

Gasal E, Mehta B, Franklin J (2016) **A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)**. In: 58th ASH Annual Meeting; Blood. 2016; 128(22) ISSN: 1528-0020; San Diego (California) USA, 3-6 December 2016

- Goswami, P, Salek, S, Fielding, A.K, Kell, J, Al-Ismail, S, **Oliva EN**, Ionova T, Else R, Karakantza M, Jennings D, Waldmann A (2016) **Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation**. In: 58th ASH Annual Meeting; Blood, 128(22), 5985; San Diego (California), USA, 3-6 December 2016

2017

- Balleari E, Salvetti C, Filiberti R, Allione B, Angelucci E, Cavalieri M, Cavalleri M, Cilloni D, Clavio M, Crisà E, Da Col A, Danise P, Di Tucci A, Finelli C, Lemoli R, Miglino M, **Oliva EN**, Pellegrino M, Poloni A, Santini V (2017) **Different Repo Doses (High Vs Standard) for Treatment of Anemia in MDS Patients: a Survey from the Italian MDS Registry**. In: 14th International Symposium of MDS, Leukemia Research Volume 55, Supplement 1, April 2017, Page S57; Valencia, Spain, 2-6 April 2017
- Fenaux P, Santini V, Aloe Spiriti MA, Giagounidis A, Schlag R, Radinoff R, Gercheva-Kyuchukova L, Anagnostopoulos A, **Oliva EN**, Symeonidis A, Hunault Berger M, Götze K, Potamianou A, Haralampiev H, Wapenaar R, Milonis I, Platzbecker U (2017). **Challenging IWG2006 response criteria: results of a randomized study of epoetin alfa versus placebo in anemic lower risk MDS patients**. In: 14th International Symposium of MDS, Leukemia Research 55: S23 ISSN: 0145-2126; Valencia, Spain, 2-6 April 2017
- Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama, B, Badre S, Gasal E, Mehta B, Franklin J (2017) **A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)**. In: 22th EHA Congress; Haematologica vol. 102(suppl. 1): 484; Madrid, Spain, 22-25 June 2017
- Goswami P, Salek S, Ionova T, **Oliva EN**, Fielding AK, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Jennings DM, Else R, Kell J (2017) **Development of a new haematological malignant patient-reported outcome measure for use in clinical practice: HM-PRO**. In: 22th EHA Congress; Haematologica vol. 102, ISSN: 0017-6559; Madrid, Spain, 22-25 June 2017
- Vitrano A, Rosso R, Quota A, Fiorino D, Oliva EN, Gerardi C, Roccamo G, Spadola V, Filosa A, Tese L, Calvaruso G, Pitrolo L, Mistretta L, Cassara F, Maggio A (2017) **Changes in liver iron concentration R2 MRI measurement across different chelation regimens in patients with hematological disorders: real-life experience from LICNET**. In: 22th EHA Congress; Poster EHA Library. Jun 23, 2017; 181577; P290, Madrid, Spain, 22-25 June 2017
- Reda G, Fattizzo B, Cassin R, Saluzzi E, Flospergher E, Mattiello V, Sciume M, Ferretti E, Andersen C, Oliva EN, Cortelezzi A (2017) **Heminsight to assess patient reported outcomes of patients affected by chronic lymphocytic leukemia in daily clinical**

practice. In: 22th EHA Congress; EHA Library. May 18, 2017; 182499; PB1785, Madrid, Spain, 22-25 June 2017

- Vitrano A, Sacco M, Rosso R, Quota A, Fiorino D, **Oliva EN**, Gerardi C, Roccamo G, Spadola, Filosa A, Tesè L, Calvaruso G, Pitrolo L, Mistretta L, Cassarà F, Di Maggio R, Maggio A (2017) **Inadequacy of Ferritin Trends for Predicting Changes in LIC Risk Category in Transfusion Dependent and Well Chelated Patients with Haemoglobinopathies.** In: 59 th ASH Annual Meeting. Blood 2017 130:936 ISSN: 1528-0020; Atalanta (Georgia) USA, 9-12 December 2017
- **Oliva EN**, Zappavigna S, Moscato T, Arcadi N, Cufari P, Alati C, Maggio A (2017) **Surrogate Thresholds for Iron Chelation in Patients with Hematological Malignancies.** In: 59 th ASH Annual Meeting. Blood 2017 130:3499 ISSN: 1528-0020. Atalanta (Georgia) USA, 9-12 December 2017
- Goswami P, Salek S, Ionova T, **Oliva EN**, Fielding AK, Karakantza M, Al-Ismaïl S, Collins G, McConnell S, Langton C, Jennings D, Else R, Kell WJ (2017) **HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice.** In: 59th ASH Annual Meeting. Blood 2017 130:2176 ISSN: 1518: 0020; Atalanta (Georgia), USA, 9-12 December 2017
- Platzbecker U, Symeonidis A, Goede JS, Guerci-Bresler A, Delforge M, **Oliva EN**, Mayer J, Badre S, Mehta B, De Oliveira Brandao C (2017). **An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS).** In: 59 th ASH Annual Meeting. Blood 2017 130:4271 ISSN: 1528-0020; Atalanta (Georgia) USA, 9-12 December 2017

2018

- Santini V, Gioia DM, Masiera E, Poloni A, Ferrero D, Fragasso A, Finelli C, Salvi F, Gaidano G, Oliva EN, Catarini M, Cametti G, Bonferroni M, Danise P, Tassarà R, Allione B, Cilloni D, Castelli A, Centurioni R, Ciravegna G, Visani G, Musto P, Balleari E, Boveri E, Ponzoni M, Gianelli U, Della Porta MG (2018) **Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome.** In: 23th EHA Congress; EHA Library. Santini V. Jun 15, 2018; 214954; PF495. Stockholm, Sweden, 14-17 June
- Di Rocco M, Cappellini MA, Carubbi F, Alpa M, Andria G, Barbato A, Burlina A, Giona F, Giuffrida G, Roccatello D, Borin LM, Spada M, Papadia F, Linari S, Salek S, Ionova T, **Oliva EN** (2018). **Observational study to develop treatment- related patient reported outcome measure in Gaucher disease (QOL-ONE PRO 1G);** In: 23th EHA Congress; EHA Learning Center. OLIVA E. Jun 14, 2018; 216144, Abstract: PB2398; Stockholm, Sweden, 14-17 June
- **Oliva EN**; Martino B, Salutati P, Alati C, Mauro E, Cortelezzi A, Capelli D, Niscola P, Selleri C, Volpe A, Cascavilla N, Musto P, Vigna E, Mannina D, Specchia G, Dubbini MV, Zannier

ME, Di Bartolomeo P, Di Raimondo F, Freyrie A, Leoni P, Candoni A (2018). **Randomized open-label, phase III Multicenter trial to Evaluate Azacitidine post-remission therapy in elderly patients with Acute Myeloid Leukemia** In: 23th EHA Congress; EHA Learning Center. EHA Learning Center. OLIVA E. Jun 16, 2018; 215308,14-17 June; Stockholm, Sweden

- Platzbecker U, **Oliva EN**, Symeonidis A, Delforge M, Mayer J, Goede JS, Guerzi-Bresler A, Badre S, Mehta BP, De Oliveira Brandao C (2018). **A Multicenter, randomized, double-blind placebo- controlled study of Darbepoetin alfa for the treatment of anemic patients with low or intermediate -1 risk myelodysplastic syndrome.** In: 23th EHA Congress; EHA Learning Center. Oliva E. Jun 17, 2018; 214478, 14-17 June; Stockholm, Sweden
- Goswami P, Ionova T, **Oliva EN**, Salek S (2018) **Comparison of the paper-based and electronic version of a new patient-reported outcome measure in haematological malignancies for use in clinical practice, HM PRO: an equivalence study;** EHA Learning Center. In: 23th EHA Congress; Goswami P. Jun 15, 2018; 215137Abstract: PF699; Stockholm, Sweden, 14-17 June 2018
- **Oliva EN**, Franek J, Patel D, Zaidi O, Abi Nehme S, Almeida AM **The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR).** ASH 2018 <https://doi.org/10.1182/blood-2018-99-111839>
- **Oliva EN**, Agberemi R, Wintrich S (2018) **Assessing Needs for Support in MDS Patients.** In: 60 th ASH Annual Meeting. Blood 2018 132:2313; doi: <https://doi.org/10.1182/blood-2018-99-112967>, San Diego (California) USA, 1-4 December 2018
- Goswami P, **Oliva EN**, Ionova T, Salek (2018) **Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies.** In: 60th ASH Annual Meeting. Blood 2018 132:4860; doi: <https://doi.org/10.1182/blood-2018-99-117180>; San Diego (California), USA, 1-4 December 2018
- **Oliva EN**, Salek S, Goswami P, Ionova T (2018) **Impact of AML on Patients' Lives: The Value of HM PRO Measurement.** In: 60th ASH Annual Meeting. Blood 2018 132:5900; doi: <https://doi.org/10.1182/blood-2018-99-117600>, San Diego (California) USA, 1-4 December 2018
- Goswami, P, **Oliva EN**, Ionova T, Salek S (2018) **Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies.** In: 60th ASH Annual Meeting. Blood 2018 132:2294; doi: <https://doi.org/10.1182/blood-2018-99-117094>; San Diego (California), USA, 1-4 December 2018

2019

- **Oliva EN** Agberemi R, Wintrich S (2019) **Quality of Life and perception of health**

care in patients with Myelodysplastic Syndromes in the UK. In: 24th EHA Congress, EHA Library. OLIVA E. Jun 15, 2019; 267125; PS1508, Amsterdam (Netherlands), 13-16 June 2019;

- **Oliva EN**, Cufari, Andriani A, Stelitano C, Frongia S, Alati C, Martini V, Gangemi D, Rodà F, Montechiarelo E, Greve B, Praticò G., Salek S, Ionova T, Martino B (2019) **Assessment of HM -PRO Italian version in patients with haematological malignancies in clinical practice.** In: 24th EHA Congress, HemaSphere: June 2019 - Volume 3 - Issue - p 693 doi: 10.1097/01.HS9.0000564276.03663.c2 Poster Session II: Quality of life, palliative & supportive care, ethics and health economics, Amsterdam (Netherlands), 13-16 June 2019;
- Goswami P, Ionova T, **Oliva EN**, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismaïl S, Collins G. P, McConnell S, Langton C, Salek S (2019) **Minimal clinically important difference and responsiveness for HM-PRO in patients with haematological malignancies.** In: 24th EHA Congress, HemaSphere: June 2019 - Volume 3 - Issue - p 315-316 doi: 10.1097/01.HS9.0000561168.46160.37 Poster Session I: Quality of life, palliative & supportive care, ethics and health economics;
- Li Z, Tang D, Tang J, Morison J, **Oliva EN** (2019) **Estimating Life-Year Loss of Lower-Risk Myelodysplastic Syndromes.** In: 24th EHA Congress, HemaSphere: June 2019 - Volume 3 - Issue - p 693 doi: 10.1097/01.HS9.0000564272.96038.ea Abstract PS1503; Amsterdam, Netherlands, 13-16 June 2019
- Li Z, Tang D, Tang J, Cavalli L, **Oliva EN** (2019) **Estimating Life-Year Loss of Primary Myelofibrosis in Europe** In: 24th EHA Congress, HemaSphere: June 2019 - Volume 3 - Issue - p 697-698 doi: 10.1097/01.HS9.0000564312.18910.1d Abstract PS1513; Amsterdam, Netherlands, 13-16 June 2019
- **Oliva EN**, Cufari P, Andriani A, Stelitano C, Frongia S, Alati C, Martini V, Gangemi D, Rodà F, Greve B, Praticò G, Salek S, Ionova T, Martino B (2019) **Valutazione della versione aggiornata dell'HM-PRO, per pazienti con neoplasie ematologiche, nella pratica clinica.** In: 47th SIE Congress, Rome, October 7-9, 2019
- **Oliva EN**, Alati C, Santini V, Poloni A, Riva M, Niscola P, Gai V, Sanpaolo G, Balleari E, Crisà E, Ferrero D, Germing U, Fenaux P, Palumbo GA, Salutati P, Impera S, Capodanno I, Reda G, Libarati Molteni A, Specchia G, Buccisano F, Voso MT, Mancini S, Bocchia M, Candoni A, Martino B, Cufari P, D'Errigo MG, Zini G, Latagliata R (2019) **Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial** In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019
- **Oliva EN**, Candoni A, Salutati P, Di Raimondo F, Reda G, Capelli D, Niscola P, Selleri C, Musto P, Vigna E, Volpe A, Cascavilla N, Mannina D, Carluccio P, Zannier ME, Mauro E, Fryrie A, Mazzone C, Martino B, Alati C (2019) **Azacitidine for Post Remission Therapy in Elderly Patients with Acute Myeloid Leukemia: Final Results of the Qoless AZA-Amle Randomized Trial.** In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019
- Pemberton-Whiteley Z, Geissler; J, Wintrich S, **Oliva EN**, Salek S, Ionova T (2019)

Identifying differences in the quality of life of patients with acute leukemia: a global survey. In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019

- Pemberton-Whiteley Z, **Oliva EN**, Geissler J, Wintrich S, Salek S, Ionova T, Tate AR, Bradley J (2019) **Identifying differences in the quality of life of patients with acute leukemia: a global survey** In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019. Oral and Poster Abstracts Session: 906 Poster III, 4785
- Goswami P, Ionova T, **Oliva EN**, Else R, Fielding AK, Jennings D, Karakantza M, Al-Ismaïl S, Collins GP, McConnell S, Langton C, Salek S (2019) **Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO.** In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019. Oral and Poster Abstracts Session: 905 Poster II, 484
- Latagliata R, Niscola P, **Oliva EN**, Riva M, Capodanno I, Volpe A, Pilo F, Baratè C, Campagna A, Pelizzari AM, Poloni A, Sarlo C, Mansueto G, Piccioni AL, Rosati S, Carmosino I, Carbone A, Tognazzi L, Salutati P, Mancini A, Cufari P, Pennese E, Fenu S, Aloe Spiriti MA, Galimberti S, Molteni A, Balleari E, Breccia M, Foà R, Maurillo L, Finelli C (2019) **Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement.** In: 61th ASH Annual Meeting. Orlando (Florida), Usa, 7-10, December 2019. Blood (2019) 134 (Supplement_1): 3010. <https://doi.org/10.1182/blood-2019-129902>
- Angelucci E, Capasso M, Della Porta MG, Forni GL, Girelli D, **Oliva EN**, Pilo F, Clavio M, Riva M, Pelizzari AM; Niscola P, Cilloni D, Binotto G, Crsà E, Santini V (2019) **A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story.** Blood (2019) 134 (Supplement_1): 4256. <https://doi.org/10.1182/blood-2019-125575>
- Deshpande S, Turner, Byrnes M, Pelligra C, Rines-MacEachern A, Chitnis M, Kulasekararaj A, Tang D, Morison J, **Oliva EN** (2019) **A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes.** Blood (2019) 134 (Supplement_1): 5838. <https://doi.org/10.1182/blood-2019-124300>

2020

- Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman L, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Díez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, **Oliva EN**, Shortt J, Niederwieser D, Mittelman M, Fianchi L, Zhong J, Laille E, La Torre I, Skikne B, Beach CL, Giagounidis A (2020) **A phase III Placebo-Controlled Trial of CC-486 in Patients with Red Blood Cell Transfusion-Dependent (RBC-TD) Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes (LR-MDS).** In the 25th EHA Congress. Session Title: Novel treatments for MDS I, Final Abstract Code: S180

- Oliva EN, Cufari P, Andriani A, Stelitano C, Frongia S, Alati C, Martini V, Gangemi D, Rodà F, Montechiarrello E, Greve B, Praticò G, Salek S, Ionova T, Martino B (2020) **Assessment of HM-PRO Italian version in patients with Haematological Malignancies in clinical practice.** June 2019 HemaSphere 3(S1):693 DOI: [10.1097/01.HS9.0000564276.03663.c2](https://doi.org/10.1097/01.HS9.0000564276.03663.c2) In the 25th EHA Congress
- **Oliva EN (2020) Assessment of comorbidities in myeloid neoplasms.** EHA SWG Session Allogeneic Tx for elderly MDS/AML in the era of novel therapies. Oral Presentation In the 25th EHA Congress.
- Besada M, Lorenzi M, Tang D, Huey K, Schroeder T, **Oliva EN (2020) Systematic Literature Review of Clinical Outcomes, Economic Burden, and Quality of Life Burden of Anemia in Elderly Patients.** In ISPOR Europe 2020, abstract November 16-19 Milan
- Besada M, Lorenzi M, Tang D, Huey K, Schroeder T, **Oliva EN (2020) Systematic Literature Review of Clinical Outcomes, Economic Burden, and Humanistic Burden of Anemia in Patients with Myelodysplastic Syndromes.** In ISPOR Europe 2020, abstract November 16-19 Milan
- **Oliva EN, Kambhampati S, Oriol A, La Torre I, Skikne B, MD, Beach CL, Kumar K, Dong Q, Chen C, Ranjan S, Kiendrebeogo Z, Braun T, MD PhD (2020) Oral azacitidine (CC-486) Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial.** Oral Presentation. Session Name: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies Session. In the 62th ASH Annual Meeting, Virtual experience, December 5-8, 2020
- Cappellini MD, Taher A, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson A, Tang D, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom, **Oliva EN (2020) Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial.** Oral Presentation. Session Name: 904. Outcomes Research - Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia. In the 62th ASH Annual Meeting, Virtual experience, December 5-8, 2020
- **Oliva EN, Platzbecker U, Garcia-Manero G, Mufti G, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, JTBackstrom, Fenaux P (2020) Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study.** Session Name: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster I. In the 62th ASH Annual Meeting, Virtual experience, December 5-8, 2020
- Pemberton-Whiteley Z, Nier S, Geissler J, Wintrich S, Verhoeven B, Christensen R, Salek

S, **Oliva EN**, Ionova T, Bradley J, Tate AR (2020) **Investigating the Quality of Life of Patients with Acute Leukemia, with a Focus on Age and Patient-Reported Experience.** Blood (2020) 136 (Supplement 1): 25–26. <https://doi.org/10.1182/blood-2020-141293>. In the 62th ASH Annual Meeting, Virtual experience, December 5-8, 2020

2021

- **Oliva EN**, Huey k, Deshpande S, Turner M, Chitnis M, Schiller E, Tang D, Jones S, Shas F. **A Systematic Literature Review of the Relationship between SERUM Ferritin and Outcomes in Myelodysplastic Syndromes.** In virtual ISPOR 2021 Research Abstracts: January 13, 2021
- **Oliva EN**, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Tang D, Jones S, Shah F. **A SET of Systematic and Targeted Reviews to Identify the Burden of Iron Chelation Therapy in Myelodysplastic Syndromes.** In virtual ISPOR 2021 Research Abstracts: January 13, 2021
- Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Yucel A, Moro Bueno L, **Oliva EN. A Systematic Literature Review of the Relationship between SERUM Ferritin and Outcomes in Beta-Thalassemia.** In virtual ISPOR 2021 Research Abstracts: January 13, 2021
- Maria Domenica Cappellini, Ali T. Taher, Antonio Piga, Farrukh Shah, Ersi Voskaridou, Vip Viprakasit, John B. Porter, Olivier Hermine, Ellis J. Neufeld, Alexis A. Thompson, Derek Tang, Peiwen Yu, Shien Guo, Jeevan K. Shetty, Dimana Miteva, Tatiana Zinger, Jay T. Backstrom, **Esther Natalie Oliva. Effects of luspatercept on health-related quality of life outcomes for patients with transfusion-dependent β -thalassaemia in the BELIEVE trial.** Presented at the British Society for Haematology (BSH) Virtual Annual Scientific Meeting, 25–28 April 2021.
- Pocock C, Montesinos P, Braun T, Kambhampati S, Oriol A, La Torre I, Skikne B, Beach CL, Zhong J, Chen C, Ranjan S, Potluri R, **Oliva EN. (2021) Estimated hospitalization-related costs with oral Azacitidine (ORAL-AZA) vs Placebo (PBO) for remission maintenance in patients with Acute Myeloid Leukemia (AML) in Spain and in the United Kingdom (UK).** Oral Presentation In the 25th EHA Congress. June 10-13, 2021. Session35. Quality of life, palliative care, ethics and health economics EHA-2136
- Laane E, Ionova T, **Oliva EN**, Andreas M, Kreuzberger N, Piechotta V, Monsef I, Skoetz N, Salek S. (2021) **Appraisal of the consistent use and reporting of patient-reported outcomes in Multiple Myeloma clinical trials: does it matter?** In the 25th EHA Congress. June 10-13, 2021. EHA-2136EHA Library. Laane E. 06/09/21; 324908; EP1187
- Andreas M, Salek S, Kreuzberger N, Piechotta V, **Oliva EN**, Ionova T. (2021) **Patient-reported outcomes in clinical trials for multiple myeloma: Where we are.** Meeting Abstract | 2021 ASCO Annual Meeting I. Journal of Clinical Oncology. Volume 39, Issue 15_suppl

- Panuccio VA, Tripepi R, Lucisano S, Postoprino A, Parlono G, Fazio MR, Catalano F, azzano D, Greve B, Sabattini E, **Oliva EN**, Mallamaci F (2021). **Does etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report.** M0802. Nephrology Dialysis Transplantation, Volume 36, Issue Supplement_1, May 2021. gfab096.0011, <https://doi.org/10.1093/ndt/gfab096.0011>
- Porkka K, **Oliva EN**, Skikne B, Beach C, Zhong J, Ranjan S, Potluri R, Jalan H, Chen C. (2021) **Estimated hospitalization-related costs with oral Azacitidine (ORAL-AZA) vs Placebo (PBO) for remission maintenance in patients with Acute Myeloid Leukemia (AML) In Sweden and Norway.** Poster in the 24th ISPOR Europe 2021, Copenhagen, Denmark, November 30-December 3 2021. Value in Health, Volume 24, Issue 12, S2 (December 2021)
- **Oliva EN**, Mammi' C, Cuzzola M, 3 Nannya Y, Kulasekararaj AG, D'Errigo MG, Cannatà MC, Zini G, Latagliata R, Niscola P, Santini V, Riva, Capodanno I, Greve S, Smith AE, Ogawa S, (2021) **NGS Evaluation of the Eql-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS.** In the 63th ASH Annual Meeting, Atlanta, Georgia – or virtually, December 11-14 2021
- Ghanima W, McDonald V, Jain S, Carpenedo M, **Oliva EN**, Hultberg A, Gandini D, Hofman E, Van Bragt T, Parys W, van Hoorick B, Miyakawa Y, Broome CM (2021) **Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia** In the 63th ASH Annual Meeting, Atlanta, Georgia – or virtually, December 11-14 2021

2022

- Ghanima W, McDonald V, Jain S, Carpenedo M, **Oliva EN**, Hultberg A, Gandini D, Hofman E, Van Bragt T, Parys W, van Hoorick B, Godar M, Rocca F, Miyakawa Y, Broome CM (2022). **Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod PH20 Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia.** In the XVII National Congress of the Italian Society of Experimental Hematology; March 31 to April 2, 2022; Rome, Italy.
- Wittlin B, McDonald V, Ghanima W, Broome C, Hultberg A, Gandini D, Parys W, Hofman E, Miyakawa Y, Jain S, Carpenedo M, **Oliva EN** (2022) **Pharmacokinetic / Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia.** In the 62nd Annual Scientific Meeting of the British Society for Haematology, April 3-5 2021 Manchester
- **Oliva EN**, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS,

Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P. (2022). **Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.** <https://www.mdpi.com/journal/jcm>
<https://doi.org/10.3390/jcm11010027>.

- Urciuoli E, Di Bona E, Greve S, De Vivo A, Sica S, Fontana R, Barcellini W, Marano L, **Oliva EN** (2022) **Observational Study to Evaluate Patient - Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria.** In the 26th EHA Congress 35. Quality of life, palliative care, ethics and health economics EHA-2996
- **Oliva EN**, Salutati P, Di Raimondo F, Reda G, Capelli D, Ianni G, Tripepi G, Alati C, Mammi C, D'Errigo MG, Niscola P, Selleri C, Musto P, Vigna E, Volpe A, Cascavilla N, Mannina D, Candoni A (2022) **Final Results of the QoLESS AZA-AMLE Randomized Trial to Evaluate the Efficacy of 5- Aza for Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients** 04. Acute myeloid leukemia - Clinical EHA-Abstract P564. In the 26th EHA Congress, June 9-12, 2022, Vienna.
- **Oliva EN**, Chen C, Rahim SN, Seuro B, Vasconcelos A, Gaugler L, Skikne B, Prebet T, Cameron H, Beach CL, Thompson G (2022). **Oral azacitidine versus midostaurin as maintenance treatment for FLT3-mutant acute myeloid leukemia in complete remission: an indirect treatment comparison.** Poster in the the 26th EHA Hybrid Congress, Congress, June 9-12, 2022, Vienna.
- **Oliva EN**, Salek S, Laane E, Andreas M, Csenar M, Skoetz N, Ionova T (2022). **Patient-reported outcomes in myeloproliferative neoplasms: a systematic review.** Poster in the the 26th EHA Hybrid Congress, Congress, June 9-12, 2022, Vienna.
- **Oliva EN**, Riva M, Carmosino I, Zini G, Niscola P, Santini V, Poloni A, Gaidano V, Patriarca A, Capodanno I, Salutati P, Sanpaolo G, Reda G, Ferrero D, Guarini A, Beltrami G, Bocchia M, Castelli A, Germing U, Impera S, Palumbo GA, Molteni A, Liberati A, Ricco A, Statoullas A, Candoni A, Rivellini F, Di Renzo N, Buccisano F, Avvisati G, Frairia C, Messa E, Mannina D, Romano A, Caocci G, Selleri C, Mancini S, Fianchi L, Rodeghiero F, Vigna E, Fenaux P, Greve S, Cufari P, Mammi C, Cannatà MC, D'Errigo MG, Bova I, Latagliata R. (2022). **Long term follow-up interim analysis of the EQOL-MDS trial for the evaluation of eltrombopag for the treatment of thrombocytopenia of MDS.** Comunicazione orale, 49° Congresso SIE 2022, 26-28 settembre 2022, Roma.
- Ghanima W, McDonald V, Jain S, **Oliva EN**, Hultberg A, Gandini D, Hofman E, Van Bragt T, Parys W, van Hoorick B, Godar M, Rocca F, Miyakawa Y, Broome CM. (2022). **Simulazioni farmacocinetiche/farmacodinamiche (PK/PD) conducono alla selezione della dose di somministrazione di Efgartigimod PH20 sottocutaneo in uno studio di fase 3 in pazienti con trombocitopenia immune primaria.** Abstract, comunicazione orale. 49° Congresso SIE 2022, 26-28 settembre 2022, Roma.

- Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein RJ, **Oliva EN**, Pozharskaya V, Ha X, Nadal JA, Miteva D, Fenaux P. (2022). **Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study.** In the 64th ASH Annual Meeting
- Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein RJ, **Oliva EN**, Pozharskaya V, Ha X, Nadal JA, Miteva D, Fenaux P. (2022). **Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study.** In the 64th ASH Annual Meeting
- Santini V, Fenaux P, Zeidan AM, Komrokji RS, Buckstein RJ, **Oliva EN**, Ha X, Nadal JA, Miteva D, Yucel A, Nadal JA, Platzbecker U. (2022). **Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial.** In the 64th ASH Annual Meeting
- Lanino L, Salutati P, Perego A, Fattizzo B, Riva M, Ubezio M, Cilloni D, Musto P, **Oliva EN**, Voso MT, Pelizzari A, Poloni A, Breccia M, Capodanno I, Elena C, Fozza C, Pane F, Di Bassiano F, Crisà E, Ferrero D, Giai V, Passamonti F, Vaccarino A, Griguolo D, Mecucci C, Paolini S, Sessa M, Turrini M, Bocchia M, Di Renzo N, Diral E, Foli C, Molteni A, Occhini U, Rivoli G, Selleri C, Bellini M, Bono R, Calvisi A, Castelli A, Di Bona E, Fianchi L, Galimberti S, Grimaldi D, Latagliata R, Marchetti M, Norata M, Tanasi I, Tosi P, Naldi I, Santini V, Della Porta MG. (2020). **Real-world efficacy and safety of luspatercept in adult patients with transfusion-dependent anemia due to very low-, low and intermediate-risk myelodysplastic syndrome (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy: a multicenter study by Fondazione Italiana Sindromi Mielodisplastiche (FISIM).** Poster in the 64th ASH Annual Meeting
- Sauta E, Bersanelli M, Travaglino E, Meggendorfer M, Robin P, Zhao LP, Caballero JC, Berrocal, Maggioni G, Bernardi M, Angelucci E, Vago L, Di Grazia C, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Chiusolo P, Giaccone L, Voso MT, Riva M, **Oliva EN**, Zampini M, Riva E, Mannina E, Bolli N, Rambaldi A, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. (2022). **Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes** presentazione orale sessione "Myelodysplastic Syndromes – Clinical and Epidemiological III", 64th ASH Annual Meeting.

Pubblicazioni su riviste

1. Romeo M, **Oliva EN**, Panuccio V, Zoccali C (1994). **The expanding uremic population - a southern European perspective**. Contributions to Nephrology vol. 109, p. 9-14, ISSN: 0302-5144 (IF: 1.58; citations: 2)
2. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G, GISEN, **Oliva EN** (1997). **Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies**. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). KIDNEY INTERNATIONAL. SUPPLEMENT, vol. 63, p. S54-S57, ISSN: 0098-6577 (IF: 10.545; citations: 142)
3. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G, GISEN, **Oliva EN** (1997). **Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy**. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). The Lancet, vol. 349, p. 1857-1863, ISSN: 0140-6736 (IF: 79.321; citations: 1374)
4. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G, GISEN, **Oliva EN** (1998). **Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies**. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney International, vol. 53, p. 1209-1216, ISSN: 0085-2538, doi: 10.1046/j.1523-1755.1998.00874. (IF: 10.158; citations: 513)
5. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G, **Oliva EN** (1998). **Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial**. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. The Lancet, vol. 352, p. 1252-1256, ISSN: 0140-6736. (IF: 79.321; citations: 707)
6. Ruggenenti P, Perna A, Benini R, Remuzzi G. GISEN, **Oliva EN** (1998). **Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies**. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Journal of the American Society of Nephrology vol. 9, p. 2096-2121, ISSN: 1046-6673 (IF: 10.121; citations: 152)
7. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, **Oliva EN**, Schiavone EM, Pollio F, Palmieri S, Gianfaldoni G, Leoni F (2001) **Aggressive Salvage Treatment Is Not Appropriate for The Majority of Elderly Patients with Acute Myeloid Leukemia Relapsed From First Complete Remission**. In: 6th EHA Congress; Haematologica January 2001 86: 814-820 ISSN: 1592-8721 (IF: 9.941; citations: 31)
8. Morabito F, Irrera G, **Oliva EN**, Console G, Martino M, Pucci G, Messina G, Barbaro P, Palazzo S, Iacopino P (2001). **Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy**. Bone Marrow Transplant 2001;9: 883-8 ISSN: 0268-3369, doi: 10.1038/sj.bmt.1703246 (IF: 5.483; citations: 11)

9. **Oliva EN, D'Angelo A, Martino B, Nobile F, Borislav D, Perna A (2002). More concern about transfusion requirement when evaluating quality of life in anemic patients.** J Clin Oncol 2002;20:3182-3183 ISSN: 0732-183X, doi: 10.1200/JCO.2002.20.14.3182 (IF: 44.54; citations: 20)
10. Galimberti S, Marasca R, Caracciolo F, Fazzi R, Papineschi F, Benedetti E, Guerrini F, Morabito F, **Oliva EN, Di Renzo N, Federico M, Petrini M, Torelli G (2002). The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.** Bone Marrow Transplan. 2002;7:581-7 0268-3369, doi: 10.1038/sj/bmt/1703422 (IF: 5.483; citations: 15)
11. Morabito F, Martino M, Stelitano C, **Oliva EN, Kropp M, Irrera G, Console G, Fujo M, Messina G, Molica S, Callea V, Iacopino P (2002). Feasibility of a Mixed Inpatient-Outpatient Model of Peripheral Blood Stem Cell Transplantation for Multiple Myeloma.** Haematologica January 2002 87: 1192-1199 ISSN: 1592-8721 (IF: 9.941; citations: 47)
12. **Oliva EN, D'Angelo A, Nobile F, Borislav D, Perna A (2003) Quality of life in myelofibrosis with myeloid metaplasia: a cross-sectional study.** Leuk Res, 2003, 27(8), 763-4 ISSN: 0145-2126, doi: 10.1016/S0145-2126(02)00326-0 (IF: 3.156; citations: 1)
13. **Oliva EN, Dimitrov BD, Benedetto F, D'Angelo A, Nobile F (2005). Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome.** Leuk Res 2005;29:1217-9 ISSN: 0145-2126, doi: 10.1016/j.leukres.2005.03.004 (IF: 3.156; citations: 91)
14. Martino M, **Oliva EN, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Puci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F (2005). Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.** Support Care Cancer 2005;3:182-7 ISSN: 0941-4355, doi: 10.1007/s00520-004-0686-2 (IF: 3.603; citations: 14)
15. Oliva EN, Nobile F (2008). **QOL-E: A New Tool for the Assessment of Health-Related Quality of Life in Patients with Myelodysplastic Syndromes.** Pro Newsletter 39, 2008 (IF: 0; citations: 0)
16. Latagliata R, **Oliva EN, Volpicelli P, Carmosino I, Breccia M, Vincelli I, Alati C, Napoleone L, Vozella F, Nobile F, Alimena G (2008) Twice-weekly high-dose rHuEpo for the treatment of anaemia in patients with low-risk Myelodysplastic Syndromes.** Acta Haematol. 2008;120(2):104-7 ISSN: 0001-5792, doi: 10.1159/000166864 (IF: 2.195; citations: 17)
17. **Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F (2010). Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.** Transfusion, 2010; 50(7):1568-70 ISSN: 0041-1132, doi: 10.1111/j.1537-2995.2010.02617.x (IF: 3.157; citations: 83)
18. **Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, Ronco F, Impera S, Risitano A, Alati C, Breccia M, Carmosino I, Vincelli I, Latagliata R (2010). Darbepoetin For the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy And Quality Of Life.** Leukemia and Lymphoma, 2010; 51(6):1007-14 ISSN: 1042-8194, doi: 10.3109/10428191003728610 (F: 3.28; citations: 1).

19. **Oliva EN**, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R (2010). **Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.** Eur J Haematol, 2010;85:231-5 ISSN: 0902-4441, doi: 10.1111/j.1600-0609.2010.01473.x (IF: 2.997; citation: 35)
20. **Oliva EN**, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, Latagliata R (2011). **Quality Of Life in Elderly Patients with Acute Myeloid Leukemia: Patients May Be More Accurate Than Physicians.** In: 16th EHA Congress; Haematologica May 2011 96: 696-702; Doi:10.3324/haematol.2010.036715 ISSN: 1592-8721 (IF: 9,941; citations: 80).
21. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G, REIN Study Group, **Oliva EN** (2011). **Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.** Journal of American Society of Nephrology 2011 Oct;22(10):1923-30 ISSN: 1046-6673, doi: 10.1681/ASN.2011020175 (IF: 10,121; citations: 244).
22. **Oliva EN**, Schey C, Hutchings AS (2011). **A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.** Am J Blood Res 2011;1(2):160-166 ISSN: 2160-1992 (IF: NA; citations: 30).
23. Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C, **Oliva EN**, REIN Study Group (2011). **ACE inhibition is renoprotective among obese patients with proteinuria.** J Am Soc Nephrol. 2011 Jun;22(6) ISSN: 1046-6673, doi: 10.1681/ASN.2010090969 (IF: 10,121; citations: 109).
24. Breccia M, Cannella L, Latagliata R, Nanni M, Santopietro M, Loglisci G, Ferretti A, Barzotti R, **Oliva EN**, Alimena G (2011). **Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.** Leuk Res. 35, 690, 2011 ISSN: 0145-2126, doi: 10.1016/j.leukres.2010.12.019 (IF: 3.156; citations: 4).
25. Breccia M, Cannella L, Latagliata R, Loglisci G, Salaroli A, Santopietro M, **Oliva EN**, Alimena G (2011) **Unexpected erythroid and cytogenetic responses after discontinuation of short course of lenalidomide due to severe skin rash in a 5q syndrome patient.** J Clin Oncol, 2011 May 10;29(14): e402-3 ISSN: 0732-183X, doi: 10.1200/JCO.2010.33.5083 (IF: 44.540; citations: 8).
26. **Oliva EN**, Piccin A, Mazzucconi MG, Morra E, Recine U, Pogliani EM, Pane F, Gobbi M, Gugliotta L, Krampera M, Cascavilla N, Cacciola R, Cacciola E, Fioritoni G, Fanin R, Liberati AM, Angelucci E, Tura S (2012). **Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study.** Ann Hematol. 2012 Apr;91(4):527-32 ISSN: 0939-5555, doi: 10.1007/s00277-011-1341-x (IF: 3.541; citations: 7).
27. **Oliva EN**, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T, Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. (2012). **Quality of life and physicians' perception in myelodysplastic syndromes.** Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25 ISSN: 2160-1992 (IF: NA; citations: 51).
28. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva EN, Lunghi M, D'Arco AM, Levis A,

- Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P (2012). **Azacitidine for the treatment of patients with acute myeloid leukemia. Report of 82 patients enrolled in an italian compassionate program.** Cancer. 2012 Feb 15; 118(4):1014-22 ISSN: 0008-543X, doi: 10.1002/cncr.26354 (IF: 6,639; citations: 132).
29. Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, **Oliva EN**, Leoni P, Spiriti AA, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT (2012). **Outcome of therapy-related myeloid neoplasms treated with azacitidine.** Journal of Hematology & Oncology. 2012 5:44 ISSN: 1756-8722, doi: 10.1186/1756-8722-5-44 (IF: 17,388; citations: 45).
 30. Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, **Oliva EN**, Cuzzola M, Starczynowski DT (2012) **Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.** In: 54 th ASH Annual Meeting; Blood 2012 120:858-867; doi: <https://doi.org/10.1182/blood-2012-02-407999> (IF: 22,11; citations: 105).
 31. Cannella L, Latagliata R, Breccia M, R, Breccia M, Carmosino I, Loglisci G, Volpicelli P, Ferretti A, Santopietro M, Vozella F, Girmenia C, Cuzzola M, **Oliva EN**, Alimena G (2012). **Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.** Ann Hematol. 2012 Feb;91(2):309-10 ISSN: 0939-5555, doi: 10.1007/s00277-011-1263-7 (IF: 3,541; citations: 5).
 32. Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, **Oliva EN**, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT (2013). **Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.** Cancer Cell. 2013 Jul 8;24(1):90-104 ISSN: 1535-6108, doi: 10.1016/j.ccr.2013.05.006 (IF: 31.74; citations: 171)
 33. **Oliva EN**, Nobile F, Dimitrov BD (2013). **Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes.** Central European Journal of Medicine. 2013 8(6):835-844 vol. 8, p. ISSN: 1895-1058, doi: 10.2478/s11536-013-0196-z (IF: NA; citations: 10)
 34. **Oliva EN**, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D'Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA (2013). **Lenalidomide in Low-and Intermediate-1 IPSS risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and efficacy.** Leuk Lymphoma. 2013 Nov;54(11):2458-65 ISSN: 1042-8194, doi: 10.3109/10428194.2013.778406 (IF: 1.706; citations: 28)
 35. **Oliva EN**, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R (2013). **Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.** Ann Hematol. 2013 Jan;92(1):25-32 ISSN: 0939-5555, doi: 10.1007/s00277-012-1569-0 (IF: 3.541; citations: 25)
 36. Salek S, Ionova T, **Oliva EN** EHA SWG Quality of Life and Symptoms (2013). **Patients' Needs In Hematology: Whose Perspectives?** Haematologica: 828-830; Doi:10.3324/haematol.2013.090399 (IF: 9,941; citations: 17).

37. Lucioni C, Finelli C, Mazzi S, **Oliva EN** (2013). **Costs and quality of life in patients with myelodysplastic syndromes**. American Journal of Blood Research; 2013 Aug 19;3(3):246-59 ISSN: 2160-1992 (IF: NA; 20)
38. Breccia M, Fianchi L, Lunghi M, Gaidano G, Levis A, Finelli C, Santini V, Musto P, Mansueto G, **Oliva EN**, Leoni P, Spiriti MA, Hohaus S, Leone G, Alimena G, Voso MT (2013). **Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine**. Leuk Lymphoma. 2012 Dec 10. August 2013; 54(8): 1786–1787 ISSN: 1042-8194, doi: 10.3109/10428194.2012.749406 (IF: 1.706; citations: 8).
39. Vozella F, Latagliata R, Carmosino I, Volpicelli P, Montagna C, Romano A, Roberto A, Finsinger P, Mancini M, Breccia M, **Oliva EN**, Alimena G (2015). **Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?** Hematol Oncol. 2015 Mar;33 p. 48-51, ISSN: 0278-0232, doi: 10.1002/hon.2134
40. Latagliata R, Alati C, Carmosino I, Montagna C, Romano A, Finsinger P, Vozella F, Volpicelli P, Breccia M, Alimena G, **Oliva EN** (2015). **Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes**. J Diabetes. vol. 7, p. 493-496, ISSN: 1753-0393, doi: 10.1111/1753-0407.12203 (IF: 4.006; citations: 1)
41. **Oliva EN**, Lausker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R (2015). **Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence**. Cancer Med. 2015 vol. 4, p. 1789-1797, ISSN: 2045-7634, doi: 10.1002/cam4.523. (IF: 4.452; citations: 15).
42. Vitrano A, Calvaruso G, Tesé L, Gioia F, Cassarà F, Campisi S, Butera F, Commendatore V, Rizzo M, Santoro V, Cigna V, Quota A, Bagnato S, Argento C, Fidone C, Schembari D, Gerardi C, Barbiera F, Bellissima G, Giugno G, Polizzi G, Rosso R, Abbate G, Caruso V, Chiodi E, Gamberini MR, Giorgi B, Putti MC, Filosa A, De Ritis MR, **Oliva EN**, Arcadi N, Fustaneo M, Mistretta L, Maggio RD, Sacco M, Veronica DS, Giangreco A, Maggio A (2016). **Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET**. Eur J Haematol. 2016 Jan 28 vol. 97, p. 361-370, ISSN: 0902-4441 doi: 10.1111/ejh.12740 (IF: 2,997; citations: 13)
43. Salek S, **Oliva EN**, Ionova T (2016). **Patient-Centered Research and Practice In The Era Of Genomics: A Novel Approach**. Haematologica July 2016 101: 792- 793 ISSN: 0390-6078; Doi:10.3324/haematol.2016.142844 (IF: 9,941; citations: 1).
44. Fedele R, Cuzzola M, Irrera G, Pontari A, D'Ascola DG, Oliva EN, Martino M (2016). **Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy**. Leuk Lymphoma. 2016; Aug 57 (vol.4): 969-972 ISSN: 1042-8194, doi: 10.3109/10428194.2015.1085533 (IF: 1,706; citations: 1)
45. Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, **Oliva EN**, Cuzzola M, Grimes HL, Fontanillo C, Komurov K, MacBeth K, Starczynowski DT (2016) **A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes**. Nature Medicine 2016 Jul;22(7):727-34 ISSN: 1078-8956, doi: 10.1038/nm.4127 (IF: 53.44; citations: 52).

46. Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, **Oliva EN**, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R. (2017) **Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.** *Oncotarget*. 2017 Jun 14;8(47):81926-81935 ISSN: 1949-2553, doi: 10.18632/oncotarget.18477 (IF: 3.33; citations: 12).
47. Velikova G, Valderas JM, Potter C, Batchelder L, A'Court, C, Baker M, Bostock J, Coulter A, Fitzpatrick R, Forder J, Fox, D, Geneen L, Gibbons E, Jenkinson C, Jones K, Kelly L, Peters M, Mulhern B, Labeit A, Rowen D, Meadows K, Elliott J, Brazier J, Knowles E, Keetharuth A, Brazier J, Connell J, Carlton J, Buck LT, Ricketts T, Barkham M, Goswami P, Salek S, Ionova T, **Oliva EN**, Fielding AK, Karakantza M, Al-Ismaïl S, Collins GP, McConnell S, Langton C, Jennings DM, Else R, Kell J, Ward H, Day S, Lumley E, Phillips P, Duncan R, Buckley-Woods H, Aber A, Jones G, Michaels J, Porter I, Gangannagaripalli J, Davey A, Ricci-Cabello I, Haywood K, Thestrup Hansen S, Valderas J, Roberts D, Gumber A, Podmore B, Hutchings A, van der Meulen J, Aggarwal A, Konan S, Price A, Jackson W, Bottomley N, Phillips M, Knightley-Day T, Beard D, Gibbons E, Fitzpatrick R, Greenhalgh J, Gooding K, Gibbons E, Valderas C, Wright J, Dalkin S, Meads D, Black N, Fawkes C, Froud R, Carnes D, Price A, Cook J, Dakin H, Smith J, Kang S, Beard D, The ACHE Study Team, Griffiths C, Guest E, Harcourt D, Murphy M, Hollinghurst S, Salisbury C, Carlton J, Elliott J, Rowen D, Gao A, Price A, Beard D, Lemanska A, Chen T, Dearnaley DP, Jena R, Sydes M, Faithfull S, Ades AE, Kounali D, Lu G, Rombach I, Gray A, Jenkinson C, Rivero-Arias O, Holch P, Holmes M, Rodgers Z, Dickinson S, Clayton B, Davidson S, Routledge J, Glennon J, Henry AM, Franks K, Velikova G, Maguire R, McCann L, Young T, Armes J, Harris J, Miaskowski C, Kotronoulas G, Miller M, Emma Ream E, Patiraki, E Geiger A, Berg GV, Flowerday A, Donnan P, Mc Crone P, Apostolidis K, Fox P, Furlong E, Kearney N, Gibbons C, Fischer F, Coste J, Valderas Martinez J, Rose M, Leplege A, Shingler S, Aldhouse N, Al-Zubeidi T, Trigg A, Kitchen H, Davey A, Porter I, Green C, Coast J, Smith S, Hendriks J, Black N, Shah K, Rivero-Arias O, Ramos-Goni JM, Kreimeier S, Herdman M, Devlin N, Finch AP, Brazier JE, Mukuria C, Zamora B, Parkin D, Feng Y, Bateman A, Herdman M, Devlin N, Patton T, Gutacker N, KoShah K (2017). **Proceedings of Patient Reported Outcome Measure's (PROMs) Conference Oxford 2017: Advances in Patient Reported Outcomes Research.** *Health Qual Life Outcomes*. 2017; 15(Suppl 1): 185. Published online 2017 Oct 5. doi: 10.1186/s12955-017-0757-y (IF: 3.186; citations: 3).
48. Platzbecker U, Symeonidis A, **Oliva EN**, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J (2017). **A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.** *Leukemia*. 2017 Sep;31(9):1944-1950. vol. 31 ISSN: 0887-6924, doi: 10.1038/leu.2017.192
49. Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, **Oliva EN**, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storrington JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F (2017) **Itaca: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.** *AMERICAN JOURNAL OF HEMATOLOGY*, vol. 92, p. 1037-1046, ISSN: 0361-8609, doi: 10.1002/ajh.24842 (IF: 11,528; citations: 70)
50. **Oliva EN**, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo G, Salutati P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Aloe Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R (2017) **Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial:** *Lancet Haematol* 2017, February 2, 2017; DOI: 10.1016/S2352-3026(17)30012-1. (IF: 18,959; citations: 116)

51. Vitrano A, Sacco M, Rosso R, Quota A, Fiorino D, **Oliva EN**, Gerardi C, Roccamo G, Spadola V, Filosa A, Tesé L, Calvaruso G, Pitrolo L, Mistretta L, Cassarà F, Di Maggio R, Maggio A. (2018). **Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET.** EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 100, p. 124-130, ISSN: 1600-0609, doi: 10.1111/ejh.12989 (IF: 2,997; citations: 3)
52. Kaivers J, Lauseker M, Hildebrandt B, Fenaux P, Pfeilstöcker M, Valent P, Platzbecker U, Latagliata R, **Oliva EN**, Xicoy B, Götze K, Ganster C, Haase D, Bug G, Kündgen A, Gattermann N, Haas R, Germing (2018). **The IPSS-R has prognostic impact in untreated patients with MDS del(5q).** Leuk Res. 2018 Sep; 72:27-33. doi: 10.1016/j.leukres.2018.07.019. Epub 2018 Jul 23 (IF: 3,156; citations: 2)
53. Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, **Oliva EN**, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P (2018). **Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations;** Blood Rev. 2018 Oct 28. pii: S0268-960X (18)30069-9. doi: 10.1016/j.blre.2018.10.002 (IF: 8.250; citations: 14).
54. Goswami P, **Oliva EN**, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Lyness J, Collins GP, McConnell S, Langton C, Al-Obaidi MJ, Oblak M, Salek S. (2018) **Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.** J Comp Eff Res. 2019 Apr 30 (IF: 1,744; citations: 6).
55. Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, Gercheva-Kyuchukova L, Anagnostopoulos A, **Oliva EN**, Symeonidis A, Berger MH, Götze KS, Potamianou A, Haralampiev H, Wapenaar R, Milionis I, Platzbecker U. **A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin- α in anemic patients with low-risk MDS.** Leukemia. (2018) Dec;32(12):2648-2658 (IF: 11,528; citations: 66)
56. Salek S, Ionova T, Johns RJ, **Oliva EN** (2019) **Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency.** Quality of Life Research, 2018, <https://doi.org/10.1007/s11136-018-2025-y> (IF: 4,147; citations: 6)
57. Germing U, **Oliva EN**, Hiwase D, Almeida A (2019) **Treatment of Anemia in Transfusion-Dependent and-Non-Transfusion-Dependent Lower Risk MDS: Current and Emerging Strategies.** HemaSphere: November 15, 2019 - Volume Latest Articles - Issue - p doi: 10.1097/HS9.0000000000000314 (IF: NA; citations: 14)
58. Balleari E, Filiberti RA, Salvetti C, Allione B, Angelucci E, Bruzzzone M, Calzamiglia T, Cavaliere M, Cavalleri M, Cilloni D, Clavio M, Crisà E, Da Col A, Danise P, Pilo F, Ferrero D, Finelli C, Gioia D, Lemoli RM, Masiera E, Messa E, Miglino M, Musto P, **Oliva EN**, Poloni A, Salvi F, Sanna A, Scudeletti M, Tassara R, Santini V (2019) **Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: a propensity score-matched analysis.** Cancer Med. 2019 Dec; 8(18): 7567–7576. Published online 2019 Oct 27. doi: [10.1002/cam4.2638](https://doi.org/10.1002/cam4.2638) (IF: 4.452; citations: 1).
59. Goswami P, **Oliva EN**, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Salek S (2020) **Development of a novel haematological malignancy specific patient-reported outcome measure (HM-PRO): Content Validity.**

Front. Pharmacol. 11:209. doi: 10.3389/fphar.2020.00209 (IF: 5,810; citations: 3)

60. **Oliva EN, Tripepi GL (2020) Letter to the Editor on the original article “A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia” by Bryant AI, et al, 2018.** Leukemia Research Article Number: 106355. First published version available online: 20-APR-2020 | <https://doi.org/10.1016/j.leukres.2020.106355> (IF: 3.156; citations: 0)
61. Caracciolo M, Macheda S, Labate D, Tescione M, La Scala S, Morabito A, Garreffa C, Marciano MC, **Oliva EN (2020) Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.** Front. Immunol., 25 August 2020 | <https://doi.org/10.3389/fimmu.2020.01942> (IF: 6.76; citations: 16)
62. Goswami P, **Oliva EN**, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnel S, Lantong C, Al-Obaidi MJ, Oblak M, Salek S (2020) **Haematological Malignancy Specific Patient-Reported Outcome Measure (HM- PRO): Construct Validity Study.** Front. Pharmacol., 08 September 2020 | <https://doi.org/10.3389/fphar.2020.01308> (IF: 5,810; citations: 2)
63. Goswami P, **Oliva EN**, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Salek S. (2020) **Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.** Ther Adv Hematol. 2020 Oct 7;11:2040620720955002. doi: 10.1177/2040620720955002. (IF: 7.167; citations: 3)
64. Goswami P, **Oliva EN**, Ionova T, Else R, Kell J, Fielding AK, Jennings DM, Karakantza M, Al-Ismail S, Collins GP, McConnell S, Langton C, Al-Obaidi MJ, Oblak M, Salek S (2020) **Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.** Front Pharmacol. 2020 Oct 20;11:571066. (IF: 5,810; citations: 0)
65. Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Cincia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, **Oliva EN**, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumè M, Secchi R, Selleri C, Tafuri A, Santini V. (2020) **SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience** HemaSphere. 4:5(e483). <http://dx.doi.org/10.1097/HS9.0000000000000483> (IF: NA; citations: 2).
66. A.H. Wei, H. Döhner, C. Pocock, P. Montesinos, B. Afanasyev, H. Dombret, F. Ravandi, H. Sayar, J.-H. Jang, K. Porkka, D. Selleslag, I. Sandhu, M. Turgut, V. Giai, Y. Ofran, M. Kizil Çakar, A. Botelho de Sousa, J. Rybka, C. Frairia, L. Borin, G. Beltrami, J. Čermák, G.J. Ossenkoppele, I. La Torre, B. Skikne, K. Kumar, Q. Dong, C.L. Beach, and G.J. Roboz. (2020) **Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.** N Engl J Med 2020;383:2526-37. DOI: 10.1056/NEJMoa2004444 (IF: 91,245; citations: 77).
67. Pepe A, Rizzo M, Galimberti S, Baratè C, **Oliva EN**, Arcioni F, Storti S, Renne S, Midiri M, Restaino G, Positano V, Mangione M, Meloni A. (2021) **Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.** Ann Hematol 2021 May;100(5):1139-1147. doi: 10.1007/s00277-021-04495-y. Epub 2021 Mar 19. (IF: 3.541; citations: 1)

68. Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca M, Chiereghin C, Di Nanni N, Gnocchi M, Zampini M, Rossi M, Maggioni G, Termanini A, Angelucci E, Bernardi M, Borin L, Bruno B, Bonifazi F, Santini V, Bacigalupo A, Voso MT, **Oliva EN**, Riva M, Ubezio M, Morabito L, Campagna A, Saitta C, Savevski V, Giampieri E, Remondini D, Passamonti F, Ciceri F, Bolli N, Rambaldi A, Kern W, Kordasti S, Sole F, Palomo L, Sanz G, Santoro A, Platzbecker U, Fenaux P, Milanesi L, Haferlach T, Castellani G, Della Porta MG. (2021) **Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes**. Journal of Clinical Oncology. Published at ascopubs.org/journal/jco on February 4, 2021: DOI <https://doi.org/10.1200/JCO.20.01659> (IF: 44.540; citations: 19).
69. Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Diez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, **Oliva EN**, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A, (2021) **Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients with Lower-Risk Myelodysplastic Syndromes**. Accepted on February 7, 2021 and published at ascopubs.org/journal/jco on March 25, 2021: DOI <https://doi.org/10.1200/JCO.20.02619> . Journal of Clinical Oncology. (IF: 44.540; citations: 13).
70. Clavio M, Crisà E, Miglino M, Guolo F, Ceccarelli M, Salvi F, Allione B, Ferrero D, Balleari E, Finelli C, Poloni A, Selleri C, Danise P, Cilloni D, Di Tucci AA, Cametti G, Freilone R, Fanin R, Bigazzi C, Zambello R, Crugnola M, Oliva EN, Centurioni R, Alesiani F, Catarini M, Castelli A, Abbadessa A, Capalbo SF, Musto P, Angelucci E, Valeria Santini V (2021) **Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice**. Cancer 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19. (IF: 6,639; citation: 1)
71. **Oliva EN**, Ronnebaum SM, Zaidi O, Patel DA, Abi Nehme S, Chen C, Almeida AM. (2021) **A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia**. Am J Blood Res 2021;11(4):325-360 www.AJBlood.us /ISSN:2160-1992/AJBR0135389 (IF: NA; citations: 0)
72. Palandri F, Rossi E, Bartoletti E, Ferretti A, Marco R, Lucchini E, Carrai V, Barcellini W, Patriarca A, Rivolti E, Consoli U, Cantoni S, **Oliva EN**, Chiurazzi F, Caocci G, Giuffrida G, Borchellini A, Auteri G, Baldacci E, Carli G, Nicolsi D, Sutto E, Carpenedo M, Cavo E, Mazzucconi MG, Zaja F, De Stefano V, Rodeghiero F, Vianelli N (2021) **Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia**. Blood 2021 Aug 19;138(7):571-583. doi: 10.1182/blood.2021010735. PMID: 33889952 (IF: 22,11; citations: 3)
73. **Oliva EN**, Latgliata R, Sabattini E, Mammì C, Cuzzola M, D'Errigo MG, Cannatà MC, Bova I, Capodanno I, Palumbo GA, Pane F, Reda G, Fianchi L, Riva M, Poloni A. (2021) **Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality**. Am J Blood Res. 2021; 11(4): 417-426 (IF: NA; citation: 0)
74. **Oliva EN**, Platzbecker U, Fenaux P, Garcia-Manero G, LeBlanc TW, Patel BJ, Kubasch AS, Sekeres MA (2021). **Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned**. Blood Reviews. Volume 50, November 2021, 100851 (IF: 8.250; citations: 0).

75. **Oliva EN**, Platzbecke U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P (2021) **Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.** *J. Clin. Med.* 2022, 11, 27. <https://doi.org/10.3390/jcm11010027>
76. **Oliva EN**, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Tang D, Yucel A, Hughes C, Shah F (2022) **A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes.** <https://www.mdpi.com/2077-0383/11/3/895/htm>.
77. Fattizzo B, Cavallaro F, **Oliva EN**, Barcellini W. (2022). **Managing fatigue in patients with Paroxysmal Nocturnal Hemoglobinuria: a patient-focused perspective.** *Journal of Blood Medicine.* Volume 2022:13 Pages 327-335. <https://doi.org/10.2147/JBM.S339660>
78. Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E, Yucel A, Moro Bueno L, **Oliva EN.** (2022) **Relationship between serum ferritin and outcomes in β -thalassemia: a systematic literature review.** *Journal of Clinical Medicine.* 2022; 11(15):4448. <https://doi.org/10.3390/jcm11154448>
79. Maggioni G, Bersanelli M, Travaglino E, Alfonso A, Annika P, Arnan K, Montserrat S, Sauta E, Sala C, Matteuzzi T, Meggendorfer M, Gnocchi M, Zhao LP, Tentori CA, Nachtkamp K, Dall'Olio D, Mosca E, Ubezio M, Campagna A, Russo A, Rivoli G, Bernardi M, Borin L, Voso MT, Riva M, **Oliva EN**, Zampini M, Riva E, Saba E, D'Amico S, Lanino L, Tinterri B, Re F, Bicchieri M, Giordano L, Angelotti G, Morandini P, Kubasch AS, Passamonti F, Rambaldi A, Savevski V, Arjan AS, van de Loosdrecht A, Brogi A, Santini V, Kordasti S, Sanz G, Sole F, Gattermann N, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Germing U, Diez-Campelo M, Della Porta MG. (2022). **A sex-informed approach to improve the personalised decision-making process in myelodysplastic syndromes: a multicentre, observational cohort study.** <https://www.sciencedirect.com/science/article/pii/S2352302622003234>
80. Salek S, Ionova T, **Oliva EN**, Andreas M, Skoetz N, Kreuzberger N, Laane E. (2022). **The reporting, use and validity of patient-reported outcomes in multiple myeloma in clinical trials: a systematic literature review.** *Cancers* 2022, 14, 6007. <https://doi.org/10.3390/cancers14236007>
81. Panuccio V, Tripepi R, Postorino A, Greve B, Sabattini E, **Oliva EN.** (2022). **Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case- report.** *Journal: Frontiers in Medicine, section Nephrology*
82. Pemberton-Whiteley Z, Nier, S, Geissler J, Wintrich S, Verhoeven B, Christensen RO, Salek, **Oliva EN**, Ionova T, Bradley J. (2023). **Understanding Quality of Life in Patients with Acute Leukemia, a Global Survey.** *J Patient Cent Res Rev.* 2023;1 0:21-30. doi: 10.17294/2330-0698.1951
<https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1951&context=jpcrr>

Pubblicazioni web

- Aerts E, Eleftheriou A, Eriksson LL, Kattamis A, Korschan-Kuhle B, N Gattermann, Giannico I, Hofmann A, **Oliva EN** (March 2020) **Blood & Beyond report: “Rethinking blood management in Europe to improve outcomes for patients.** www.bloodandbeyond.com
https://media.bloodandbeyond.com/wp-content/uploads/BloodandBeyond_Rethinking_blood_use_in_Europe.pdf
- **E-book “Pink Positive”, 52apitol 8. Qualità della vita nelle pazienti oncologiche** (2020)
<https://www.pinkpositive.it/e-book/>

Brevetti

- Oliva EN, Dimitrov BD (2001). QOL-E. TX 7-814-559
- Salek S, Oliva EN, Ionova T (2017) HM-PRO Txu 2-041- 797

Brochure informativa per i pazienti

Oliva EN (2017); E ADESSO? : Guida semplice a un momento difficile; 2017-2018: Celgene Corporation

Libri

De Stefano V, Gugliotta L, **Oliva EN**, Tura S, Vannucchi A. **Trombocitemia Essenziale. Camminiamo insieme Gli ematologi ai pazienti con trombocitemia**

Aloe Spiriti, MA, Cortelezzi A, Finelli C, Ghio R, Levis A, Liso V, Musto P, **Oliva EN**, Poloni A, Santini V, Semenzato G, Terenzi A (2010). **Sindromi Mielodisplastiche Dalla Teoria alla Pratica Clinica.** Vol. II Edizione

Aloe Spiriti, MA, Cortelezzi A, Finelli C, Ghio R, Levis A, Liso V, Musto P, **Oliva EN**, Poloni A, Santini V, Semenzato G, Terenzi A (2007). **Sindromi Mielodisplastiche Dalla Teoria alla Pratica Clinica.** P. 75-82, MILANO: Elsevier Masson

De Stefano V, Gugliotta L, **Oliva EN**, Tura S, Vannucchi AM (2007). **Manuale di trombocitemia: Camminiamo insieme: Gli ematologi ai pazienti con trombocitemia**

Oliva EN, Della Porta M. L'impatto della Trasfusione-Dipendenza nel paziente con sindrome mielodisplastica a basso rischio (2018). Anno XXI, N. 5, giugno 2018 Therapy Perspectives

Riconoscimenti

Modafferi B, Latella V, **Oliva EN** (2020) Premio Cefar **“Diagnosi Emometrica di Laboratorio in un caso di Mielodisplasia: il ruolo del laboratorio”**

Modafferi B, Latella V, **Oliva EN** (2020) Premio Ceriotti **“Diagnosi Emometrica di Laboratorio in un caso di Mielodisplasia: il ruolo del laboratorio”**

Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 “Codice in materia di protezione dei dati personali” e del GDPR (Regolamento UE 2016/679).

Reggio Calabria, 2 febbraio 2023

